

Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



PHILHEALTH CIRCULAR No. 2019- 0005

TO

ALL PHILHEALTH MEMBERS, ACCREDITED AND

CONTRACTED HEALTH CARE PROVIDERS,

PHILHEALTH REGIONAL OFFICES AND ALL OTHERS

CONCERNED

SUBJECT

Outpatient Benefit Package for the Secondary Prevention of

Rheumatic Fever/Rheumatic Heart Disease

I. BACKGROUND

Rheumatic fever (RF)/rheumatic heart disease (RHD) continue to be the leading cause of acquired heart disease in children and adults in the Philippines, especially affecting those living in overcrowded and marginalized sectors of society. RF/RHD is included in the top 20% of high burden conditions in the Philippines (IHME 2017). The prevalence rate is estimated at 1/1,000 school children aged 5 to 10, and accounts for 40% of all cardiac admissions. (DOH, Philippines, 2010) As of 2006, RHD ranks as the 24th top cause of death and the 4th leading cause of adolescent mortality in the Philippines (Carrascoso-Cuartero, 2015). The causative agent leading to RF/RHD is group A beta-hemolytic streptococci (GAS), which causes a pharyngeal infection followed by a latent period of approximately two to three weeks and an autoimmune process marked by inflammatory reaction in the heart, joints, skin, subcutaneous tissue and central nervous system. The recurrence of streptococcal infection cascades the progressive destructive effect on the heart valves that leads to the chronic sequelae of the disease or the chronic valvulopathy of RHD (Stage A and B). Progressive valve changes leads to valve regurgitation and/or stenosis, chamber dilatation (Stage C) and to hemodynamic disturbances causing heart failure (Stage D), arrhythmias, and other complications such as stroke and infective endocarditis.



II. RATIONALE

The 71st World Health Assembly 2018 recognizes that RF/RHD is a preventable disease and with evidence for cost-effective interventions that are crucial for the eradication of the disease.

Product Team for Special Benefits

Page 1 of 13









By providing coverage for the secondary prophylaxis of RF/RHD under the National Health Insurance Program, the natural history of the disease is intended to reverse as well as the percentage of patients requiring valve surgery among adults in the next ten years. Through the PhilHealth outpatient benefit package for RF/RHD, as approved by the PhilHealth Board (PhilHealth Board Resolution No. 2368 s. 2018), catastrophic health expenditures for the management of RF/RHD complications as well as the need for valve surgery can be minimized significantly.

III. **OBJECTIVE**

This circular aims to define the policies and procedures for the implementation of outpatient benefit package for the secondary prevention of RF/RHD.

IV. SCOPE

This Circular shall apply to all accredited health care institutions (HCI) that are contracted to provide the defined mandatory services for the secondary prevention of RF/RHD in the outpatient setting.

V. **DEFINITION OF TERMS**

- A. Antibiotic prophylaxis refers to the prevention of infection complications using antimicrobial therapy (most commonly antibiotics)
- B. Lost to follow up means the patient has not come back for injection for four consecutive visits from the next scheduled injection
- C. Mandatory services minimum standards of care that contracted health care institutions should provide to beneficiaries of the National Health Insurance Program
- D. Modified Jones Criteria a guide used to diagnose RF/RHD based on signs and symptoms, classified as major and minor manifestations, for patients with RF/RHD
- E. Multidisciplinary-interdisciplinary team (MDT) approach to patient care—each discipline respecting the role and expertise of the other, in the delivery of complete managed care and course of treatment which comprises all mandatory and other services required to produce the desired health outcome
- F. Other services additional services other than the minimum standards of care that may be necessary to provide quality care, which are based on clinical guidelines and current standards of care that are acceptable by the Corporation



Product Team for Special Benefits

Page 2 of 13

- G. Rheumatic fever (RF) an inflammatory, systemic disease, caused by group A beta – hemolytic streptococcus.
- H. Rheumatic heart disease (RHD) a disease condition of the heart due to the complication of rheumatic fever in which the heart valves are damaged
- Secondary prophylaxis for RF/RHD refers to the continuous antimicrobial prophylaxis to provide the most effective protection from recurrences of RF

VI. SPECIFIC GUIDELINES

A. CONTRACTING HEALTH CARE INSTITUTIONS AS PROVIDERS FOR THE OUTPATIENT BENEFIT PACKAGE FOR RHEUMATIC FEVER/RHEUMATIC HEART DISEASE


With the mandate of the National Health Insurance Program to pay for quality health care services, the Corporation has the prerogative to negotiate and enter into contracts with PhilHealth-accredited HCIs for the provision of the mandatory services of the outpatient benefit package for RF/RHD following the guidelines for contracting.

Coordination and collaboration with the contracted HCIs for this benefit package shall be required for quality improvement and operational purposes, such as, but not limited to, pertinent training, regular patient audits, patient referrals, patient tracking, and pooled procurement of drugs and supplies, etc.

The contracted HCI shall designate at least one RF/RHD coordinator who shall guide and navigate patients to ensure adherence to agreed treatment plan, track and record patient visits and follow-ups, encode patient data, track the validity of approved pre-authorization requests per patient and coordinate with the concerned PhilHealth Regional Office to ensure completeness and accuracy of all attachments needed for pre-authorization and claims application to facilitate reimbursement.

MINIMUM STANDARDS OF CARE

The outpatient benefit package for RF/RHD shall include the following healthcare services (Table 1).



Product Team for Special Benefits

Table 1. Mandatory and other services for the outpatient benefit package for RF/RHD

Mandatory Services (Minimum Standards of Care)	Other services
A. Secondary prophylaxis using: Injections with penicillin G benzathine (benzathine benzylpenicillin), 1.2 M units, vial (modified release or MR) (intramuscular or IM) OR, if with indications (Annex "J") oral secondary prophylaxis with phenoxymethyl penicillin (penicillin V) (as potassium salt) or oral erythromycin B. Diagnostic test Diagnostic test Diagnostic test at least once a year during the second tranche)	 A. Medicines aspirin prednisone antacids B. Laboratory tests Erythrocyte sedimentation rate (ESR) C-reactive protein (CRP) Antistreptolysin O (ASO) Titer Complete blood count (CBC) with platelets C. Diagnostic tests Electrocardiogram (EKG/ECG) Chest x-ray

C. AVAILMENT OF THE OUTPATIENT BENEFIT PACKAGE FOR RHEUMATIC FEVER/RHEUMATIC HEART DISEASE

- 1. Criteria for availment of the package
 - Fulfills membership eligibility for availment of PhilHealth benefits
 - b. Fulfills any of the following clinical criteria or stage of cardiac involvement for the availment of the outpatient benefit package for RF/RHD:
 - i. Stage A Valve involvement based on Modified Jones Criteria
 - ii. Stage B, with all of the following:
 - Progressive valve disease (mild to moderate severity and ii.1 asymptomatic)
 - ii.2 Normal left ventricular (LV) size and function



-{:

Product Team for Special Benefits

Page 4 of 13







- iii. Stage C, with all of the following:
 - Moderate to severe valve involvement iii.1
 - iii.2 Left ventricle enlargement
 - iii.3 No heart failure
 - iii.4 Functional class I-II
- iv. Stage D, with <u>all</u> of the following:
 - iv.1 Severe valve involvement or multiple
 - Left ventricle enlargement iv.2
 - iv.3 With heart failure
 - iv.4 Functional class III-IV

2. Pre-authorization

- Once the member fulfills the eligibility and clinical criteria for availment of the outpatient benefit package for RF/RHD, the contracted HCI shall proceed with the process of seeking approval for pre-authorization
- b. While the contracted HCI is seeking approval of their pre-authorization request from PhilHealth, the designated staff in the contracted HCI should already administer the first dose of IM injection of penicillin G benzathine to the patient who requires the IM injection route and this should be documented accordingly in the patient record.

Patients who are beneficiaries of the sponsored program or are indigents should not be charged out-of-pocket for receiving the service;

- The pre-authorization process involves the following steps:
 - i. The contracted HCI must completely accomplish all forms required for pre-authorization prior to submission of the Pre-authorization Checklist and Request (Annex "A");
 - While the process of pre-authorization is not yet automated, a designated liaison of the contracted HCI shall submit the preauthorization request with the required attachments to the office of the Head of the PhilHealth Benefits Administration Section (BAS) in the region or to the Local Health Insurance Office (LHIO). Attachments to the pre-authorization request are the properly accomplished member empowerment form (ME Form, Annex "B") and the PhilHealth Benefit Eligibility Form (PBEF).
- The ME Form shall be discussed by the attending health care iii. professional/s and accomplished together with the parent/guardian or patient tog-be enrolled in the Outpatient Benefit Package for RF/RHD. The ME Form aims to support parent/guardian or



Product Team for Special Benefits

102.13


patients to become active participants in health care decision making by being educated and informed of the conditions and all management options. Further, the ME Form aims to encourage the attending health care professionals in the contracted HCIs to dedicate adequate time to discuss treatment options with patients. The primary objectives of the member empowerment are to achieve better health outcomes and patient satisfaction.

- The approved/disapproved Pre-authorization Checklist and Request ıv. shall be returned to the contracted HCI within five (5) working days;
- It is the contracted HCI's responsibility to remind their patients, as applicable, to update their premium contributions to ensure that these patients are eligible during the entire period of availment of the RF/RHD outpatient benefit package.
- 3. Validity of the approved pre authorization request

The approved pre – authorization request shall be valid within 12 months from the date of approval. The 2D echo must be done at least within 12 months for stages A and B and within 6 months for stages C and D from date of application receipt of the pre-authorization request.

All contracted HCIs are responsible for tracking the validity of their approved pre-authorization requests. The contracted HCI shall inform PhilHealth when the validity of the approved pre-authorization request has lapsed. A new Pre-Authorization Checklist and Request may be submitted to PhilHealth if the mandatory services were not provided at the end of the validity period of the prior request.

- Five days shall be deducted from the 45-day annual benefit limit upon approval of the application for pre-authorization. The member or the dependent should have at least one day remaining from the 45-day annual benefit limit prior to submission of the Pre-authorization Checklist and Request.
- b. An approved Pre-authorization Checklist and Request guarantees payment of the first tranche of the outpatient benefit package provided that mandatory services for the specified treatment phase are given to the patient and all other PhilHealth requirements are complied with.
- 4. Package Rate, Rules on Co-pay and Electronic Medical Records
 - a. The package code for RF/RHD is RFRHD.




b. The corresponding reimbursement rate for the Benefit Package for RF/RHD is Php12,000.00 per patient in a given fiscal year. Payment shall be in two tranches that shall be reimbursed directly to the contracted HCI.

Each tranche payment will be paid in the amount of Php 6,000.00.

Table 2. Filing schedule

	Filing Sch	nedule for Secondary P	rophylaxis	
Mode of reimbursement	propriyants with propri		Oral secondary prophylaxis with phenoxymethyl penicillin (penicillin V) (as potassium salt) or oral erythromycin	
Tranche 1	Within 60 days after	Within 60 days after	Within 60 days after	
	the 10th IM injection	the 7th IM injection	the last intake in the 6th month of oral secondary prophylaxis	
Tranche 2	Within 60 days after	Within 60 days after	Within 60 days after	
	the 17th IM injection	the 13th IM injection	the last intake in the 12 th month of oral secondary prophylaxis	



-[

Product Team for Special Benefits

- The contracted HCI shall establish or develop its internal guidelines and process regarding allocation of hospital and professional fees after PhilHealth reimbursements.
 - Rules on pooling of professional fees in government hospitals shall be followed (DOH AO 2016-0033).
- d. Indigent and Sponsored Program members should not be charged out of pocket for services received when availing of the RF/RHD outpatient benefit package.
- e. A co-pay ceiling shall be reflected in the individual contracts of HCIs for eligible non-sponsored members and their qualified dependents to cover for additional services beyond the benefit package and patient requests for private consults. However, it is highly encouraged that no additional fees be charged to PhilHealth members and their dependents.
- f. All mandatory services shall be provided according to the minimum standards set in the package. Based on evidence updates and current standards of local practice, the mandatory services shall also undergo updates during policy review in collaboration with experts and stakeholders.
- Contracted HCIs are required to have an electronic medical record (EMR) of all their RF/RHD patients and participate in the National Registry of RF/RHD maintained by the Philippine Heart Association and the Philippine Foundation for RF/RHD Prevention and Control. For standardization, the contents of the EMR shall be set by PhilHealth and the reference HCI in collaboration with experts and stakeholders. While the contracted HCI is setting up an electronic recording of their RF/RHD patients, a logbook shall be allowed only on the first year of contract and provided that it reflects the required data fields set in the EMR.
- h. All RF/RHD patients shall be monitored and tracked for relevant patient outcomes and other indicators set by the Corporation.

5. Claims Filing and Reimbursement

The contracted HCI can file a claim for reimbursement only for approved pre-authorization requests and after rendering all mandatory services that are specified in Section VII, Table 1 of this Circular.



Product Team for Special Benefits

4.


- b. The claims application filed by the contracted HCI should include the following documents:
 - i. Transmittal Form of claims for the outpatient benefit package for RF/RHD (Annex "H") per claim or per batch of claims;
 - ii. Documentary attachments for all claims application for the outpatient benefit package for RF/RHD:
 - Photocopy of the approved Pre-authorization Checklist and Request (Annex "A");
 - ii.2 PhilHealth Benefit Eligibility Form (PBEF) printout or its equivalent (e.g. Claim Form 1 or CF1) as proof of membership eligibility;
 - Photocopy of the properly accomplished ME Form (Annex ii.3 "B") for tranche 1 claim application.

Note: A copy of the properly accomplished ME Form shall be provided to the patient by the contracted HCI and the signed original copy should be attached to the patient's chart as a permanent record.

- iii. Properly accomplished PhilHealth Claim Form 2 (CF2) (Annex "I");
- iv. Checklist of Mandatory Services and Other Services (Annex "C1" and "C2");
- v. RF/RHD Satisfaction Questionnaire (Annex "D");

Note: The satisfaction questionnaire should reflect the feedback of the patient on the services rendered for every tranche.


- vi. Checklist of Requirements for Reimbursement (Annex "E")
- c. Rules on late filing shall apply.
- d. If the delay in the filing of claims is due to natural calamities or other fortuitous events, the contracted HCI shall be accorded an extension period of 60 calendar days as stipulated in Section 47 of the Implementing Rules and Regulations (IRR) of the National Health Insurance Act of 2013 (Republic Act 7875, as amended).
- There shall be no direct filing of claims by members.
- A filed claim shall undergo review for the completeness of all forms submitted. Signatures of the attending PhilHealth accredited doctor and



Product Team for Special Benefits

the Medical Director/Medical Center Chief and the RF/RHD Coordinator, who are attesting that all the mandatory services were provided to the patient, are required;

- g. There shall be NO Return to Sender (RTS). It is the contracted HCI's responsibility to make sure that all documents are completely filled out and in order prior to submission of claims application to PhilHealth. The PROs and LHIOs have the prerogative not to accept incomplete documents. However, the PRO/ LHIO staff should directly coordinate with the contracted HCIs when there are deficiencies in the documents filed. Once the documents are complete, the contracted HCI can file the claims application to PhilHealth for reimbursement within the required filing schedule.
- h. All claims application submitted by the contracted HCI shall be processed by PhilHealth within 30 working days from receipt of claim provided that all requirements are fulfilled by the contracted HCI. (Refer to Annex "E" for the checklist of requirements for reimbursement).
- Payment for claims shall be denied only in the following instances:
 - i. If a mandatory service was not provided by the contracted HCI;
 - ii. If the required signatures in the forms are missing;
 - Incompletely filled out forms;
 - iv. Incomplete attachments, such as ME Form, photocopy of the approved Pre-authorization Checklist and Request, and other forms required under the benefit package;
 - v. Late filing.
- The contracted HCI may apply for motion for reconsideration for all denied claims based on existing PhilHealth policies.
- k. All claims shall be paid directly to the contracted HCI.
- In the event that the patient expires in the course of treatment or the patient is lost to follow up (as defined in Section V. Item B), the contracted HCI may still file claims for the payment of mandatory services rendered to the patient. The contracted HCI should submit a notarized sworn declaration for patients who expired or are declared lost to follow up.



The following antibiotic prophylaxis should have been completed by the expired patient for claims reimbursement:

- i. For 21-day secondary prophylaxis: completed at least 6 injections of penicillin G benzathine (benzathine benzylpenicillin)
- ii. For 28-day secondary prophylaxis: completed at least 4 injections of penicillin G benzathine (benzathine benzylpenicillin)
- iii. For secondary oral prophylaxis: completed at least 6 months of oral intake of phenoxymethyl penicillin (penicillin V) (as potassium salt) or erythromycin

The sworn declaration should describe the number of injections or oral secondary prophylaxis completed by the patient.


m. Patient transfer

- RF/RHD patients who wish to transfer to another contracted HCI shall express their intention by accomplishing the Letter of Intent for transfer of RF/RHD care to a Referral RF/RHD provider (Annex "G") in triplicate, to be to submitted to the following:
 - referring RF/RHD provider
 - referral RF/RHD provider
 - Benefits Administration Section of the PhilHealth Regional Office whose jurisdiction is within the referring RF/RHD provider

The RF/RHD Coordinator should guide the patient in accomplishing the form.

Transfer to another facility is allowed only after completing the services for tranche 1 (Section VI. Item C.4, Table 2).

ii. RF/RHD patients who shall transfer to other contracted RF/RHD providers are required to have a Checklist for Patient Transfer (Annex "M") properly accomplished by their referring contracted RF/RHD provider to be submitted to the referral RF/RHD provider. The referral RF/RHD provider should be notified in advance by the referring RF/RHD provider of the plans to transfer a RF/RHD patient.



Product Team for Special Benefits

D. MONITORING AND POLICY REVIEW

Contracted HCIs shall be monitored for compliance to the contract and to the standards of the benefit package during implementation. The EMR is intended to facilitate tracking of patients and reporting and analysis of patient level data by both PhilHealth and the contracted HCI.

Conduct of field monitoring shall be scheduled by PhilHealth to monitor service provision by contracted HCI as well as gather patient feedback. The performance indicators and measures to monitor compliance to the policies of this Circular shall be established in collaboration with relevant stakeholders and experts. This shall be incorporated in the appropriate issuance pertinent to monitoring.

Reports and results of field monitoring visits shall be inputs and shall inform the regular policy review.

MARKETING, PROMOTION AND PATIENT EMPOWERMENT

In order to educate the general public and increase their awareness on the outpatient benefit package for the secondary prevention of RF/RHD and to promote informed decision-making and participation among patients, health care professionals, and health care institutions, and other stakeholders, marketing and promotional activities shall be undertaken in accordance with the integrated marketing and communication plan of PhilHealth.

The Corporation shall likewise undertake regular monitoring and evaluation of the effectiveness of the marketing and promotion activities of the benefit package. Further, patients and stakeholders shall be given the opportunity to participate and contribute to the improvement of marketing and promotional activities of the Corporation that are pertinent to this benefit.

VII. REPEALING CLAUSE

Provisions of previous issuances inconsistent with this Circular are hereby amended, modified or repealed accordingly. Those that are consistent shall remain valid and binding.

VIII. **EFFECTIVITY**

This circular shall take effect fifteen (15) days after publication in a newspaper of general circulation and shall be deposited with the National Administrative Register, University of the Philippines Law Center.

Product Team for Special Benefits

Page 12 of 13










IX. ANNEXES (Annexes shall be uploaded in the PhilHealth website)

- A. Pre-authorization Checklist and Request (Annex "A")
- B. ME Form (Annex "B")
- C. Checklist of Mandatory Services and Other Services (Annex "C")
- D. RF/RHD Satisfaction Questionnaire (Annex "D")
- E. Checklist of Requirements for Reimbursement (Annex "E")
- F. HCI Standards as Providers for the Outpatient Benefit Package for RF/RHD (Annex "F")
- G. Letter of Intent for transfer of RF/RHD care to a Referral RF/RHD provider (Annex "G")
- H. Transmittal Form (Annex "H")
- I. Sample Claim Form 2 (Annex "I")
- J. Checklist of indications for oral secondary prophylaxis (Annex "J")
- K. General process flow for the provision of care for RF/RHD (Annex "K")
- L. Checklist of services that may be outsourced by the contracted HCI (Annex "L")
- M. Checklist for Patient Transfer (Annex "M")
- N. OPD Assessment Form (Annex "N")
- O. Registry Form for Diagnosed Cases (Annex "O")
- P. Clinical Pathway for the Rheumatic Fever Suspect (Annex "P)

ROY FERRER, MD, MSc

Acting President and CEO

Date Signed: 02/27 / a




Subject: Outpatient Benefit Package for the Secondary Prevention of Rheumatic Fever/Rheumatic Heart Disease


Product Team for Special Benefits

Page 13 of 13











RRepublic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph




Case No			
		Annex '	'A – RF/RHD"
HEALTH CA	RE INSTITUTION (HCI)		
ADDRESS OI	FHCI		
A. PATIENT	1. Last Name, First Name, Middle Name,		X Male 🗆 Female
	2. PhilHealth ID Number		
B. MEMBER (answer only if	1. Last Name, First Name, Middle Name,	Suffix	
the patient is a dependent)	2. PhilHealth ID Number	- 1111	
	PRE-AUTHORIZATION CI Rheumatic Fever/Rheumatic I		<u>—-</u>
QUALIFICA'	TION		
Place a check r	mark (✓) for the Stage of the Disease	Stage:	□ C
Fulfills any of	the following criteria:		
Echocardiograpplicable):	ram finding (tick one, whichever is	Date/s	of 2D-echo
	Modified Jones Criteria Il to Stage A valve involvement		
Definit Progre			
🖺 Norma	te RHD Echo Stage B ssive Valve Disease Il LV size and function		

Ļ

As of February 2019

Page 1 of 3 of Annex A - RF/RHD











RRepublic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph




PRE-AUTHORIZATION REQUEST Rheumatic Fever/Rheumatic Heart Disease

	DATE OF REQUEST (mm/dd/yyyy):	
	This is to request approval for provision of servisecondary prevention of RF/RHD	ices under the outpatient benefit package for the
	(NAME OF PATIENT) under the terms and conditions as agreed for ava	(NAME OF HCI)
	The patient belongs to the following category (p I No Balance Billing (NBB) I Co-pay	lease tick appropriate box):
	Certified correct by:	Certified correct by:
	(Printed name and signature) Attending Physician	(Printed name and signature) Executive Director/Chief of Hospital/ Medical Director/ Medical Center Chief
	PhilHealth Accreditation No.	PhilHealth Accreditation No.
		(Printed name and signature) Parent/Guardian
Dale: /	(For PhilHea ☐ APPROVED ☐ DISAPPROVED (State reason/s)	lth Use Only)
	(Printed name and signature) Authorized Personnel, Benefits Administration	Section (BAS)
Ħ		COMPLIANCE TO REQUIREMENTS
	Activity Initial Date Received by LHIO/BAS: Endorsed to BAS (if received by LHIO):	☐ APPROVED ☐ DISAPPROVED (State reason/s)
f	☐ Approved ☐ Disapproved	Activity Initial Date
ľ	Released to HCI:	Received by BAS:
	This pre-authorization is valid within 12 months	☐ Approved ☐ Disapproved
	from date of approval of request.	Released to HCI:

As of February 2019

Page 3 of 3 of Annex A - RF/RHD







Echocardiogram finding (Continuation)	Date/s of 2D-echo
☐ Definite RHD Stage D	
Severe valve involvement or multiple	
Left ventricle enlargement	
With heart failure	
Functional Class III-IV	
Treatment Plan: choose one	
☐ Secondary prevention intramuscular, Penicillin G	Choose one
benzathine (benzathine benzylpenicillin)	□ every 21 days
OR	□ every 28 days
☐ Secondary prophylaxis with oral medication	Choose one
, , ,	☐ phenoxymethyl penicillin
	(penicillin V)
	□ erythromycin
Certified correct by	Attending Physician:
${}$ p_r	inted name and signature
PhilHealth Accreditation No.	

Note:

Once approved, the contracted HCI shall print the approved pre-authorization form and have this signed by the parent or guardian and health care providers, as applicable. This form shall be submitted to the PhilHealth Regional Office (PRO) or the Local Health Insurance Office (LHIO) when filing the first

There is no need to attach laboratory results. However, these should be included in the patient's chart and may be checked during the field monitoring of the RF/RHD Benefits. Please do not leave any item blank.





Republic of the Philippines

PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



Numero ng kaso:	
Case No	

Annex "B-ME Form"

MEMBER EMPOWERMENT FORM

Magpaalám, tumulong, at magbigay kapangyarihan Inform, Support & Empower

Mga Panuto:

Instructions:

Ang dokumentong ito ay nasusulat sa dalawang wika:

This document is written in two languages:

- Ipaliliwanag at tutulungan ng kinatawan ng ospital ang pasyente sa pagsasagot ng ME form. The health care provider shall explain and assist the patient in filling-up the ME form.
- 2. Isulat nang maayos at malinaw ang mga impormasyon na kinakailangan. Legibly print all information provided.
- Para sa mga katanungang nangangailangan ng sagot na "oo" o "hindi", lagyan ng marka (✓) ang angkop

For items requiring a "yes" or "no" response, tick appropriately with a check mark ().

- Gumamit ng karagdagang papel kung kinakailangan . Lagyan ito ng kaukulang marka at ilakip ito sa ME
 - Use additional blank sheets if necessary, label properly and attach securely to this ME form.
- 5. Ang kinontratang ospital na magkakaloob ng dalubhasang pangangalaga sa pagpaparami ng kopya ng ME Form.

The ME form shall be reproduced by the contracted health care institution (HCI) providing specialized care.


6. Tatlong kopya ng ME form ang kailangang ibigay ng kinontratang ospital. Ang mga kopyang nabanggit ay ilalaan para sa pasyente, ospital at PhilHealth. Triplicate copies of the ME form shall be made available by the contracted HCI—one for the patient; one as file copy of the contracted HCI providing the specialized care and one for PhilHealth.

PANGALAN NG OSPITAL HEALTH CARE INSTITUTION (HCI) ADRES NG OSPITAL ADDRESS OF HCI Ŀ

of Jahuary 2019

Page 1 of 9 of Annex B - RF/RHD ME Form









A. Impormasyon ng Miyembro/ Pasy A. Member/Patient Information	ente	
MIYEMBRO (kung ang pasyente ay kalipikad	ong makikinabang) (Apelyido, I	Pangalan, Panggitnang Apelyido, Karagdagan sa
Pangalan) MEMBER (if patient is a dependent) (Last name, First	name, Middle name, Suffix)	
NUMERO NG PHILHEALTH ID NG MIYEN	1BRO 🗆 🗆 — 🗆 🗆 🗆	300000 - 00
PERMANENTENG TIRAHAN PERMANENT ADDRESS	·	
PANSAMANTALANG TIRAHAN		
TEMPORARY ADDRESS		
PASYENTE (Apelyido, Pangalan, Panggitnang A PATIENT (Last name, First name, Middle name, Suffi	pelyido, Karagdagan sa Pangalan x)
NUMERO NG PHILHEALTH ID NG PASYE PHILHEALTH ID NUMBER OF PATIENT	nte 🗆 🗆 — 🗆 🗆 [
PERMANENTENG TIRAHAN		··
PERMANENT ADDRESS PANSAMANTALANG TIRAHAN		
TEMPORARY ADDRESS	1	
Petsa ng Kapanganakan (Buwan/Araw/Taon) Birthday (mm/ dd/yyy)	Edad Age	Kasarian Sex
Numero ng Telepono	Numero ng Cellphone	Email Address
Telephone Number Kategorya bilang Miyembro:	Mobile Number	Email Address
Membership Category:		
☐ Empleado sa Employed Sector		
☐ Gobyerno ☐ Pri	bado	
	vate	
	lay-ari ng Kompanya / <i>Enterp</i> i asambahay / Household Help	rise Owner
	agamaneho ng Pamilya/ <i>Fami</i>	ly driver
C-KE		
Self Employed	sa	
Migrant Worker/OFW		
i Informal Sector / May sariling pina mga propesyonal, artista, at iba pa)	gkakakitaan (Halimbawa, Neg	gosyante, Nagmamaneho ng traysikel at taxi,
mga propesyonal, artista, at iba pa) Informal Sector / Self-Earning Individual	ls (Ex. Business owner/tricycle/tax	xi drivers/street vendors, entrepreneurs, professionals,
artists, etc.) ☐ Filipino na may dalawang pagkamam.	amayon / Naturalized Filitina C	Pitionan
Filipino with Dual Citizenship/Naturaliz	ed Filipino Citizen	····zen
Organized Group	IGroup Gold	
Marálitâ		
Indigent (4Ps/CCT, MCCT)		
☐ Inisponsuran		
Sponsored ☐ Bayan LGU		
☐ Nakatatandang mamamayan Senior	Citizen (RA 10645)	
☐ Iba pa Others	· · · · · · · · · · · · · · · · · · ·	
☐ Habambuhay na kaanib/ Lifetime Memb	er	

Page 2 of 9 of Annex B - RF/RHD ME Form


_		
В.	Impormasyong Klinikal	
	Clinical Information	
	Paglalarawan ng kondisyon ng	
	pasyente	
	Description of condition	
	Napagkasunduang angkop na plano	
	ng gamutan sa ospital	
	Applicable Treatment Plan agreed upon	
1	with healthcare provider	
	-	
3.	Napagkasunduang angkop na	
1	alternatibong plano ng gamutan sa	
	ospital	
	Applicable alternative Treatment Plan	
	agreed upon with health care provider	
	Talatakdaan ng Gamutan at Kasun	
C.	Treatment Schedule and Follow-	up Visit/s
1.	Petsa ng unang pagkakaospital o	
	konsultasyon ²	
	(buwan/araw/taon)	
	Date of initial admission to HCI or	
	consult (mm/dd/yyyy)	
1	² For ZMORPH, this refers to the	
	external lower limb pre-prosthesis	
	rehabilitation consult. For PD First,	
	this refers to the date of medical	
	consultation or visit to the PD	
1	Provider prior to the start of the first	
1	PD exchange. For RF/RHD, this	
	refers to the date of 1st check-up.	
2.	Pansamantalang Petsa ng susunod	
~.	na pagpapa-ospital o	
1	* * * *	
	konsultasyon ^b (buwan/araw/taon)	
	Tentative Date/s of succeeding admission	
	to HCI or consult ^b (mm/dd/yyyy)	
ì	b For ZMORPH, this refers to the	
1	external lower limb measurement,	
	fitting and adjustments For the PD	
	First, this refers to the next visit to the	
	PD Provider. For RF/RHD, this	
	refers to the date of first injection.	
2.2	D	Date of succeeding injections
<u>Ç</u> 3.	Pansamantalang Petsa ng kasunod	2 24 CO Succeeding injunions
1	na pagbisita c (buwan/araw/taon)	
N	Tentative Date/s of follow-up visit/s	
10	(mm dd yyyy)	
Date: 3/27,	^c For ZMORPH, this refers to the	
a.j	external lower limb post-prosthesis	
ď	rehabilitation consult. For RF/RHD,	
41		
*	this refers to the dates of succeeding	
\$	injections.	ļ.,
Ц		
.!		
ပ္က		

Page 3 of 9 of Annex B - RF/RHD ME Form




D. Edukasyon ng Miyembro D. Member Education		
agyan ing tsek (%) ang ang kop na sagot o NA kung hin khauukol 🚁 🧢 🤲 agyan ing tsek (%) oppaite oppretate answer or NA tipud applicable.	©© <u></u>	HIINID INO
. Ipinaliwanag ng kinatawan ng ospital ang uri ng aking karamdaman. My health care provider explained the nature of my condition.		
. Ipinaliwanag ng kinatawan ng ospital ang mga pagpipiliang paraan ng gamutan/interbensyon ^d My health care provider explained the treatment options/intervention ^d .		
. Ipinaliwanag ng kinatawan ng ospital ang mga posibleng mga epekto/ masamang epekto ng gamutan/ interbensyon. The possible side effects/ adverse effects of treatment/intervention were explained to me.		
. Ipinaliwanag ng kinatawan ng ospital ang kailangang serbisyo para sa gamutan ng aking karamdaman/ interbensyon. My health care provider explained the mandatory services and other services required for the treatment of my condition/intervention.		
Lubos akong nasiyahan sa paliwanag na ibinigay ng ospital. I am satisfied with the explanation given to me by my health care provider		_
i. Naibigay sa akin nang buo ang impormasyon na ako ay mahusay na aalagaan ng mga dalubhasang doktor sa aking piniling kinontratang ospital ng PhilHealth at kung gustuhin ko mang lumipat ng ospital ay hindi ito maka-aapekto sa aking pagpapagamot. I have been fully informed that I will be cared for by all the pertinent medical and allied specialties, as needed, present in the PhilHealth contracted HCI of my choice and that preferring another contracted HCI for the said specialized care will not affect my treatment in any way.	,	
7. Ipinaliwanag ng kinatawan ng ospital ang kahalagahan ng pagsunod sa panukalang gamutan/interbensyon. Kasama rito ang pagkompleto ng gamutan/interbensyon sa unang ospital kung saan nasimulan ang aking gamutan/interbensyon. My health care provider explained the importance of adhering to my treatment plan/intervention. This includes completing the course of treatment/intervention in the contracted HCI where my treatment/intervention was initiated.		
Paalala: Ang hindi pagsunod ng pasyente sa napagkasunduang gamutan/interbensyon sa ospital ay maaaring magresulta sa hindi pagbabayad ng mga kasunod na claims at hindi dapat itong ipasa bilang case rates. Note: Non-adherence of the patient to the agreed treatment plan/intervention in the HCI may result to denial of filed claims for the succeeding tranches and which should not be filed as case rates.		
Bihigyan ako ng ospital ng talaan ng mga susunod kong pagbisita. My health care provider gave me the schedule/s of my follow-up visit/s.		

Page 4 of 9 of Annex B-RF/RHD ME Form



D. Edukasyon ng Miyembro	·			
D. Eddkasyon ng Whyembro D. Member Education	,			
· ·	oma sagot o NA kung hindi mautkol <i>winidte auswer or NA if mu a tillidalla</i>		. <u>00</u>	IGUNIDI NO
9. Ipinaalam sa akin ng ospital tulong pinansiyal o ibang pa a. Sangay ng pamahalaan (lb. Civil society o non-gove c. Patient Support Group d. Corporate Foundation e. Iba pa (Hal. Media, Relig My health care provider gave me support, when needed. a. Government agency (ex. PCS b. Civil society or non-government c. Patient Support Group d. Corporate Foundation	ang impormasyon tungkol sa maaari kon ang suporta, kung kinakailangan. Hal.: PCSO, PMS, LGU, etc.) rnment organization gious Group, Politician, etc.) e information where to go for financial and other TO, PMS, LGU, etc.) nt organization			
e. Others (ex. Media, Religious	Group, Politician, etc.)			
karampatang paggagamot n	ng listahan ng mga kinontratang o g aking kondisyon o karamdaman. ealth care provider with a list of other contract			
PhilHealth sa pagpapa-m PhilHealth benefit package:	y health care provider of the PhilHealth membe	g naaayon sa		
a. Kaalipikado ako sa mga kondisyon/kapansanan. I fulfill all selections criteria	itinakdang batayan para sa aking			
b. Ipinaliwanag sa akin ang	polisiya hinggil sa "No Balance Billing" [BB] policy was explained to me.	(NBB)	-	
miyembro at kanilang k ospital: inisponsuran, n iGroup na may kaukula Note: NBB policy is a accommodation: sponsored,	ng NBB ay maaaring makamit ng mga sa alipikadong makikinabang kapag na-admaralita, kasambahay, senior citizens at ang Group Policy Contract (GPC) applicable to the following members when an indigent, household help, senior citizens and intract (GPC) and their qualified dependents.	nit sa ward ng miyembro ng dmitted in ward		
Para sa inisponsura miyembro ng iGroup at kanilang kwalipikao	n, maralita, kasambahay, senior na may kaukulang Group Policy Co long makikinabang, sagutan ang c, d	ontract (GPC) l at e.		
members with valid G	nt, household help, senior citizens and PC and their qualified dependents, as staling hindi ako gumamit ng NBB ay	nswer c, d		
magkaroon ng kaukulan	g gastos na aking babayaran. oose not to avail of the NBB and may be char			<u> </u>

Page 5 of 9 of Annex B - RF/RHD ME Form







		dukasyon ng Miyembro		
		Member Education An ag tsek (%) ang ang kop na sagoto NA kung hindi nanukol	00	HHINDI
	Rulla	scheckmark (V) opposite appropriate answer or NA if not applicable.	YEN	NO
	d. e.	Sakaling ako ay magpapalipat sa mas magandang kuwarto ayon sa aking kagustuhan, nauunawaan ko na hindi na ako maaaring humiling sa pagamutan para makagamit ng pribilehiyong ibinibigay sa mga pasyente na NBB (kapag NBB, wala nang babayaran pa pagkalabas ng pagamutan) In case I choose to upgrade my room accommodation, I understand that I can no longer demand the hospital to grant me the privilege given to NBB patients (that is, no out of pocket payment upon discharge from the hospital) Ninanais ko na lumabas sa polisiyang NBB ang PhilHealth at dahil dito, babayaran ko ang anumang halaga na hindi sakop ng benepisyo sa PhilHealth I opt out of the NBB policy of PhilHealth and I am willing to pay on top of my PhilHealth benefits Pumapayag akong magbayad ng hanggang sa halagang PHP* para sa: I agree to pay as much as PHP* for the following:	ΧΈΩ	<u> </u>
		anumang karagdagang serbisyo, tukuyin		
		* Ito ay tinantiyang halaga lamang na gagabay sa pasyente kung magkano ang kanyang babayaran at hindi dapat gawing batayan para sa pagtutuos ng kuwenta ng nagugol na gastusin sa pagkakaospital na babayaran ng PhilHealth. This is an estimated amount that guides the patient on how much the out of pocket may be and should not be a basis for auditing claims reimbursement.		
	a 7	ang mga sumusunod na katanungan ay para sa mga miyembro ng formal t informal economy at kanilang mga kalipikadong makikinabang The following are applicable to formal and informal economy and their qualified dependents		
	g	Naiintindihan ko na maaari akong magkaroon ng babayaran para sa halagang hindi sakop ng benepisyo sa PhilHealth. I understand that there may be an additional payment on top of my PhilHealth benefits.		
k	×	Pumapayag akong magbayad ng hanggang sa halagang PHP* para sa aking gamutan na hindi sakop ng benepisyo ng PhilHealth. I agree to pay as much as PHP* as additional payment on top of my PhilHealth benefits.		
ſ	148 Date: 3/2/	* Ito ay tinantiyang halaga lamang na gagabay sa pasyente kung magkano ang kanyang babayaran at hindi dapat gawing batayan para sa pagtutuos ng kuwenta ng nagugol na gastusin sa pagkakaospital na babayaran ng PhilHealth. This is an estimated amount that guides the patient on how much the out of pocket may be and should not be a basis for auditing claims reimbursement.		
	.30	12. Limang (5) araw lamang ang babawasan mula sa 45 araw na palugit sa benepisyo sa isang taon para sa buong gamutan sa ilalim ng benefit package na ito. Only five (5) days shall be deducted from the 45 confinement days benefit limit per year for the duration of my treatment/intervention under this benefit package.		

F

E. Member Roles and Responsibilities			
lagyan ng (V) ang ang kopina sagot o NA kung lilindi na Rula (V) opposite appropriate auwar ar NA ili not applicable.	nukol	Neg .00	INIO INO
l. Nauunawaan ko ang aking tungkulin upang masunod	ang nararapat at nakatako	la	
kong gamutan.	et schadula		
I understand that I am responsible for adhering to my treatmen			
2. Nauunawaan ko na ang pagsunod sa itinakdang gamu			
aking paggaling at pangunahing kailangan upang maga benefit package na ito	imit ko nang buo ang		
I understand that adherence to my treatment schedule is import	ant in terms of clinical outcom	es	
and a pre-requisite to the full entitlement of this benefit packag	-	1	
3. Nauunawaan ko na tungkulin kong sumunod sa mga	polisiya at patakaran ng		
PhilHealth at ospital upang magamit ang buong bene	fit package na ito. Kung		
sakali na hindi ako makasunod sa mga polisiya at pata		na	
ospital, tinatalikuran ko ang aking pribilehiyong maka ito.	Ramit ng nenent backage	114	
I understand that it is my responsibility to follow and comply u	ith all the policies and procedi	ures	
of PhilHealth and the health care provider in order to avail of	this full benefit package. In t	be	
event that I fail to comply with policies and procedures of Philf	Health and the health care		
provider, I waive the privilege of availing this benefit package.			
F. Pangalan, Lagda, Thumb Print at Petsa			
F. Printed Name, Signature, Thumb Print and Date	Thumb Print	Petsa	
	(kung hindi makakasulat	(buwan/ araw	
Pangalan at Lagda ng pasyente/parent/guardian:*	ang pasyente) (if patient is unable to write)		
Printed name and signature of patient*	(1) patient is unable to write)		
*Para sa mga menor de edad, ang magulang o tagapag-alaga ang			
pipirma o maglalagay ng thumb print sa ngalan ng pasyente.			
* Time entrance number the beinted names and affire the consisting of the horsest or			
		Petsa (buwan/a	
guardian on behalf of the patient.		Petsa (buwan/a	
Pangalan at lagda ng nangangalagang Doktor:			
Pangalan at lagda ng nangangalagang Doktor:			
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi:			
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi:		Date (mm/ da	d/yyy) araw/taor
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: Witnesses:		Date (mm/ d	d/yyy) araw/taon
*For minors, write the printed name and affix the signature of the parent or guardian on behalf of the patient. Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: Witnesses: Pangalan at lagda ng kinatawan ng ospital:		Date (mm/ da	d/yyy) araw/taon
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: Witnesses: Pangalan at lagda ng kinatawan ng ospital:		Date (mm/ da	d/yyy) araw/taor d/yyy)
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: IVitnesses: Pangalan at lagda ng kinatawan ng ospital: Printed name and signature of HCI staff member		Date (mm/ de Petsa (buwan/ Date (mm/ de	araw/taor
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: IVitnesses: Pangalan at lagda ng kinatawan ng ospital: Printed name and signature of HCI staff member Pangalan at lagda ng asawa/ magulang / pinakamalapit s	na kamag-	Petsa (buwan/	araw/taor
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: Witnesses: Pangalan at lagda ng kinatawan ng ospital: Printed name and signature of HCI staff member Pangalan at lagda ng asawa/ magulang / pinakamalapit anak/awtorisadong kinatawan (Bilugan ang relasyon sa panak/awtorisadong kinatawan (Bilugan ang relasyon sa panakawan ga panakawan	na kamag- pasyente)	Petsa (buwan/	araw/taor
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: Witnesses: Pangalan at lagda ng kinatawan ng ospital: Printed name and signature of HCI staff member Pangalan at lagda ng asawa/ magulang / pinakamalapit anak/awtorisadong kinatawan (Bilugan ang relasyon sa Printed name and signature of spouse/ parent/ next of kin / auth	na kamag- pasyente)	Petsa (buwan/	araw/taor
Pangalan at lagda ng nangangalagang Doktor: Printed name and signature of Attending Doctor Mga Saksi: Witnesses: Pangalan at lagda ng kinatawan ng ospital: Printed name and signature of HCI staff member Pangalan at lagda ng asawa/ magulang / pinakamalapit anak/awtorisadong kinatawan (Bilugan ang relasyon sa panak/awtorisadong kinatawan (Bilugan ang relasyon sa panakawan ga panakawan	na kamag- pasyente)	Petsa (buwan/	d/yyy) araw/tao d/yyy) araw/tao

Page 7 of 9 of Annex B - RF/RHD ME Form







	H. Numerong maaaring tawagan sa PhilHealth H. PhilHealth Contact Details
ľ	Opisinang Panrehiyon ng PhilHealth
	PhilHealth Regional Office No.
	Numero ng telepono Hotline Nos.
L	
1	I. Guhit ng Tirahan at Palatandaan I. Sketch of Home Address with Landmark
	Bilang bahagi ng patuloy na pagpapabuti ng PhilHealth sa pagbigay ng mga benepisyo at serbisyo,
	ibinibigay ko ang mga sumusunod na impormasyon para sa pagbisita sa mga tahanan ng mga
	nakinabang sa Z Benefits: (Pakiguhit ang inyong tirahan sa ibaba.)
١	As part of the continuing efforts of PhilHealth to improve the benefits delivery and services, I am providing the
	following information for the sole purpose of conducting home visits to patients who availed of the Z Benefits: (Please
	draw a sketch of your home address below.)
	8
	Dale: W
=	O O
c	
)	31
	3
_	
	Landmark/s:
	Nearest National Road (as applicable):
	Nearest Church, School or Establishment (if any):
	Nearest Barangay Hall:
	Other information to guide directions to your home:

Page 8 of 9 of Annex B-RF/RHD ME Form





£.

J. Pahintulot sa pagsusuri sa talaan ng J. Consent to access patient reco			itulot na mailagay) Registry	ang medical data sa
			ent to enter me ID Registry	dical data in the
Ako ay pumapayag na suriin ng Philf- talaang medikal upang mapatunayan a ng claim na isinumite. I consent to the examination by PhilHealth records for the sole purpose of verifying the ve submitted.	ang katotohanan of my medical	Ako ay p imporma kailangan Pinahihir maipaala: pangkalu I consent t RF/RHI package. I	umapayag na mai syong medikal sa i sa benefit packag itulutan ko din an m ang aking perso sugan sa mga kino o have my medical do D Registry as a requi	RF/RHD Registry na ge na ito. ge na ito. ge PhilHealth na onal na impormasyong ontratang ospital. the entered electronically in the frement for the this benefit the to disclose my personal
Ako ay nagpapatunay na walang pana mula sa pahintulot na nakasaad sa itaa packages ng PhilHealth. I hereby hold PhilHealth or any of its offices herein-mentioned consent which I have volun PhilHealth.	as sapagkat kusang rs, employees and/or	g-loob ko i representati	tong ibinigay upa	ng makagamit ng benefit all liabilities relative to the
Buong pangalan at lagda ng pasyente ² Printed name and signature of patient* * Para sa mga menor de edad, ang magulang of maglalagay ng thumb print sa ngalan ng pasye * For minors, the parent or guardian affixes their signature.	o tagapag-alaga ang pi ente.		Thumb print (Kung hindi na makasusulat) (if patient is unable to write)	Petsa (buwan/araw/taon) Date (mm/dd/yyy)
of the patient. Buong pangalan at lagda ng kumakata Printed name and signature of patient's report walang kasama/ no companion				Petsa (buwan/araw/taon) Date (mm/dd/yyyy)
Relasyon ng kumakatawan sa pasyent Relationship of representative to patient (tich		angkop na l	kahon)	
□ asawa □ magulang □ spouse parent		epatid ct of kin	□tagapag-alaga guardian	□ walang kasama no companion
L. Detalye ng Tagapag-ugnay ng L. PhilHealth RF/RHD Coordina	PhilHealth pata ator Contact Det	sa RF/R ails	HD outpatient k	penefit package
Pangalan ng Tagapag-ugnay ng Phill Name of PhilHealth RF/RHD Coordina	Health para sa RF/	RHD ben	efit package na ito	o na nakatalaga sa ospital
Numero ng Telepono Telephone number	Numero ng Cell Mobile number	Phone	Email A	Address
	f			

teamphilhealth

As of February 2019



Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



Case	No.			


Annex "C1 - RF/RHD"

CHECKLIST OF MANDATORY AND OTHER SERVICES Rheumatic Fever/Rheumatic Heart Disease

Tranche 1

HEALTH CAI	RE INSTITUTION (HCI)			
ADDRESS OF	ADDRESS OF HCI			
A. PATIENT	1. Last Name, First Name, Middle Name, Suffix	SEX ☐ Male ☐ Female		
	2. PhilHealth ID Number	-		
B. MEMBER (answer only if	1. Last Name, First Name, Middle Name, Suffix			
the patient is a dependent)	2. PhilHealth ID Number	-		


MANDATORY SERVICES	Status
Tick one, whichever is applicable penicillin G benzathine (benzathine benzylpenicillin), 1.2M units, vial (MR) (IM) every 28 days	Dates of injection: 1 2 3 4 5 6 7
Oral secondary prophylaxis, tick one phenoxymethyl penicillin (penicillin V) erythromycin	Start date of oral prophylaxis: Date of last intake:
	Tick one, whichever is applicable penicillin G benzathine (benzathine benzylpenicillin), 1.2M units, vial (MR) (IM) every 28 days OR Oral secondary prophylaxis, tick one phenoxymethyl penicillin (penicillin V)



·F

As of February 2019

Page 1 of 2 of Annex C - RF/RHD










	MANDATORY SERVICES	Status
a.	Tick one, whichever is applicable	Dates of injection:
. For RF/RHD	Denicillin G benzathine (benzathine benzylpenicillin), 1.2M units, vial (MR) (IM) every 21 days OR	2 3 4 5 6 7 8 9 10
B.	☐ Oral secondary prophylaxis, tick one ☐ phenoxymethyl penicillin (penicillin V) ☐ erythromycin	Start date of oral prophylaxis: Date of last intake:
C. Laboratory exam		
Labo		
Others		
Ē.	Date of initial registration in the RF/RHD Registry	Date

OTHER SERVICES, as needed	Status
	Indicate date/s done or NA if not applicable
□ ASO	
□ ESR	
□ CRP	
☐ CBC with platelet	
□ EKG	
☐ Chest X-ray	
aspirin	
prednisone	
antacid	

Conforme by		Documents reviewed by	
7/23			
7	(Printed name and signature)	(Printed name and signature)	
UT.	Parent/Guardian/Patient	RF/RHD Coordinator	
MASTER	Date signed (mm/dd/yyyy)	Date signed (mm/dd/yyyy)	
ON!			
_ ≰o∖ [Certified correct by:	Certified correct by:	
4.6	(Printed name and signature)	(Printed name and signature)	
Ì	Attending Physician	Executive Director/Chief of Hospital/	
]	on l	Medical Director/ Medical Center Chief	
	PhilHealth Accreditation No.	PhilHealth Accreditation No.	
	Date signed (mm/dd/yyyy)	Date signed (mm/dd/yyyy)	

Page 2 of 2 of Annex C - RF/RHD





Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



Case No.	


Annex "C2 - RF/RHD"

CHECKLIST OF MANDATORY AND OTHER SERVICES Rheumatic Fever/Rheumatic Heart Disease

Tranche 2

HEALTH CAI	RE INSTITUTION (HCI)	
ADDRESS OF	FHCI	
A. PATIENT	1. Last Name, First Name, Middle Name, Suffix	SEX
		☐ Male ☐ Female
	2. PhilHealth ID Number	
B. MEMBER	1. Last Name, First Name, Middle Name, Suffix	
(answer only if		
the patient is a dependent)	2. PhilHealth ID Number	<u> </u>


	MANDATORY SERVICES	Status
	Tick one, whichever is applicable	Dates of injection:
For the unatic fever	☐ penicillin G benzathine (benzathine benzylpenicillin), 1.2M units, vial (MR) (IM) every 28 days OR	2 3 4 5 6 7
A. For the	☐ Oral secondary prophylaxis, tick one ☐ phenoxymethyl penicillin (penicillin V) ☐ erythromycin	Start date of oral prophylaxis: Date of last intake:




8

As of February 2019

Page 1 of 2 of Annex C - RF/RHD









	MANDATORY SERVICES	Status
	Tick one, whichever is applicable	Dates of injection:
B. For RF/RHD	□ penicillin G benzathine (benzathine benzylpenicillin), 1.2M units, vial (MR) (IM) every 21 days OR	1
B ,	Oral secondary prophylaxis, tick one phenoxymethyl penicillin (penicillin V) erythromycin	Start date of oral prophylaxis: Date of last intake:
Others C. Lab exam	2D Echocardiography	Date/s:
D. Others		
E.	Date/s of updates* in the RF/RHD Registry	Date/s

OTHER SERVICES,	Status
as needed	
	T)1
	Place a check if
	given or
	NA if not
	applicable
aspirin	
prednisone	
antacid	

^{*}The RF/RHD Coordinator should update the information of the patient in the registry at least every six months.

	Conforme by	Documents reviewed by
<u> </u>	(Printed name and signature)	(Printed name and signature)
7/	Parent/Guardian/Patient	RF/RHD Coordinator
72	Date signed (mm/dd/yyyy)	Date signed (mm/dd/yyyy)
MASTER COPY 15 Date 3	Certified correct by:	Certified correct by:
\$ 0 \$ 0	(Printed name and signature)	(Printed name and signature)
130/S	Attending Physician	Executive Director/Chief of Hospital/
- 3		Medical Director/ Medical Center Chief
ن	PhilHealth Accreditation No.	PhilHealth Accreditation No.
	Date signed (mm/dd/yyyy)	Date signed (mm/dd/yyyy)


Share your opinion with us!

We would like to know how you feel about the services that pertain to the outpatient benefit package for the secondary prevention of rheumatic fever/rheumatic heart disease in order that we can improve and meet your needs. This survey will only take a few minutes. Please read the items carefully. If you need to clarify items or ask questions, you may approach your friendly health care provider or you may contact PhilHealth call center at 441-7442. Your responses will be kept confidential and anonymous.

For	items 1 to 2, please tick on the appropriate box.
1.	Respondent's age is: 19 years old & below between 20 to 35 between 36 to 45 between 46 to 55 between 56 to 65 above 65 years old
2.	Sex of respondent ☐ male ☐ female
For	items 3 to 7, please select the one best response by ticking the appropriate box.
3.	How would you rate the services received from the health care institution (HCI) in terms of availability of medicines or supplies needed for the treatment of your condition? ☐ adequate ☐ inadequate ☐ don't know
DC: My Dale: 777/1	How would you rate the patient's or family's involvement in the care in terms of patient empowerment? (You may refer to your Member Empowerment Form) excellent satisfactory unsatisfactory don't know
5.	In general, how would you rate the health care professionals that provided the services for this benefit package in terms of doctor-patient relationship? □ excellent □ satisfactory □ unsatisfactory □ don't know

7.

6.	In your opinion, by how much has your HCI expenses been lessened by availing of PhilHealth benefit package for RF/RHD? □ less than half □ by half □ more than half □ don't know
7.	Overall patient satisfaction (PS mark) is: excellent
8.	If you have other comments, please share them below:
	Thank you. Your feedback is important to us!
	Signature of Patient/ Parent/ Guardian Relationship to the patient:
	Date accomplished:





Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



Case No		Annex	"E – RF/RHD"
HEALTH CAI	RE INSTITUTION (HCI)		
ADDRESS OF	F HCI		
A. PATIENT	1. Last Name, First Name, Midd		EX l Male 🏻 Female
	2. PhilHealth ID Number		
B. MEMBER (answer only if	1. Last Name, First Name, Midd	le Name, Suffix	
the patient is a dependent)	2. PhilHealth ID Number		-
CHECKLIST OF REQUIREMENTS FOR REIMBURSEMENT Rheumatic Fever/Rheumatic Heart Disease			
Requirements Please Check			
1. Checklist o	1. Checklist of Requirements for Reimbursement (Annex E-RF/RHD)		
2. Photocopy of approved Pre –Authorization Checklist & Request (Annex A- RF/RHD)			
	3. Photocopy of completely accomplished ME FORM (Annex B) Note: ME Form is only required for tranche 1 claims application.		
	PhilHealth Claim Form (CF) 1 or		-
	EF) at the time of pre-authorizatio		
	f Mandatory and Other Services (
6. Photocopy	of completed Satisfaction Question	onnaire (Annex D)	
	satisfaction questionnaire should i		
	patient on the services rendered for every tranche.		
	LETED: (mm/dd/yyyy) D: (mm/dd/yyyy)		
DATE TIDE): (HIII) dd, уууу)		
Gertified corre	ct by:	Conforme by:	
i (Prin	ted name and signature)	(Printed name and	signature)
`	Attending Physician	Parent/Guard	•
PhilHealth		Date signed (mm/dd/yyyy)	
Accreditation No.	11/	-	
Date signed (n	ım/aa/yyyy)		
<u>-</u>		<u></u>	

As of February 2019 teamphilhealth

f www.facebook.com/PhilHealth

You Tube www.youtube.com/teamphilhealth

actioncenter@philhealth.gov.ph

Page 1 of 1 of Annex E - RF/RHD



Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph



Self-assessment tool for the Outpatient Benefit Package for the Secondary Prevention of Rheumatic Fever/Rheumatic Heart Disease

	to the secondary revention of incumate	z evez, zmen	made ricari	Discase
Name	of HCI:		_	
Date o	of Survey (mm/dd/yyyy):Tir	ne started:	Time e	nded:
1. Put a 2. For or the or provi 3. For j	ons for the HCI: check () under the HCI column if the standard is available outsourced services, put a () under the HCI column and wri utsourced service provider. Outsourced services, must have sions for payment such as compliance to the No Balance Bill proof of attendance to required course of training, Certificate hal chapter will be accepted.	te under the rem a Memorandum ing (NBB) Polic	of Agreement (I y.	MOA) which reflects
	REQUIREMENTS	HOI	Bill	REMANDES
1	HCI License and Accreditation			
1.1	The HCI has an updated Department of Health			
	(DOH) License to Operate (LTO)			
1.2	The HCI has an updated PhilHealth Accreditation			
2	Mandatory Ancillary Services			
2.1	RF/RHD Direct - Observed Injection Clinic			
a	Clean table surface with two chairs (one for the			
	health care provider and the other for the patient)			
Ъ	One examination bed to allow IM administration			
	of the injection in a supine position			
С	A hand wash basin with soap, running water and			
	paper towels			
d	Alcohol hand rub			
e	Emergency cart with epinephrine, IV			
	hydrocortisone, IV fluids			

f O2 tank/ source with O2 mask/ cannula 2.2 Medications Benzathine penicillin injection 1.2M units/vial a Oral phenoxymethylpenicillin (PCN-VK) 250 mg b Erythromycin capsule 250mg / suspension Human Resource 3 At least 2 physicians (adult, pedia or family medicine, general practitioner with training) Valid PRC license Valid PhilHealth accreditation Certificate of Completion of Training on the RF/RHD Implementation Guideline issued by the Philippine Heart Association or its regional chapter

Page 1 of 2





-{-

	REQUIREMENTS	HCI	PHIC	REMARKS
3.3	RF/RHD Coordinators			
a	A registered nurse or midwife in charge of			
	administering the injection			_
	Certificate of Completion of Training on the			
	RF/RHD Implementation Guideline issued by			
	the Philippine Heart Association or its regional			
	chapter			
Ь	Administrative Staff			
	with working knowledge on operation /process			
	flow for RF/RHD who will be in-charge of			
	record keeping and accomplishment of			
	PhilHealth documents/forms			
	Certificate of Completion of Training on the			
	RF/RHD Implementation Guideline issued by			
ŀ	the Philippine Heart Association or its regional			
	chapter	12 121		
3.4	Available Forms / Recording			- 4.5 - 1 - 1 - 1 - 1 - 1
a	RF/RHD OPD Assessment Form			
b	RF/RHD OPD Secondary Prophylaxis			
	Passport Book			
С	RF/RHD Registry Forms			
d	RF RHD manual entitled "OPLAN RF RHD:			
	ASAP Awareness-Surveillance-Advocacy-			
	Prevention" (Philippine Heart Association /			
	Philippine Foundation of Prevention and			, ,
	Control of RF/RHD 2017)	<u> </u>	<u> </u>	

PhilHealth Survey Team

Timireum curvey zeum		
Surveyors' Names	Designation	Signature
· · · · · · · · · · · · · · · · · · ·		
		·

HCI Management Team Names O. ...

Names O. ...


Represents with HCI / Notes of PhilHealth after Pre-contracting survey Signature Designation Names of Management Team (.



Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION Citystate Centre Building, 709 Shaw Boulevard, Pasig City Healthline 441-7444 www.philhealth.gov.ph



Case No			Kalusugen nadn Si
		An	nex "G – RF/RHD"
HEALTH CAR	E INSTITUTION (HCI)		
ADDRESS OF	HCI		
		-	
A. PATIENT	1. Last Name, First Name, Midd	le Name, Suffix	SEX ☐ Male ☐ Female
	2. PhilHealth ID Number		
(answer only if	1. Last Name, First Name, Midd	le Name, Suffix	
the patient is a dependent)	2. PhilHealth ID Number		
ETTER OF INTEN	NT FOR TRANSFER OF RF/RI	HD CARE TO A REFERI	RAL RF/RHD PROVID
This is to certify	r that T	, born on	
1120 20 10 1012	(Name of Patient)	,	(Date of Birth)
age years	old, residing at		,
		(Address)	at the
was diagnosed v	vith rheumatic fever/rheumatic h	eart disease on	at the
	(Name of referring l	RF/RHD provider)	
I am on (tick on	ne):		-
☐ 21 day cycl	le penicillin G benzathine (benza	thine benzylpenicillin), 1.	2M units and
completed	10 injections		
	le penicillin G benzathine (benza	thine benzylpenicillin), 1.	2M units and
completed	/ injection lary antibiotic prophylaxis		
	<u></u>		
I would like to 1	request for transfer of RF/RHD	Olame of referral l	RF/RHD provider)
under the care o	of		at / Itilo provider)
	(Name of Physician)		
I understand the subsequent RF	nat upon transfer to a referral F /RHD claims in my referring RF	RF/RHD provider, I will /RHD facility. In case I	have to waive all my decide to return to the
21 c · nm/n·	HD Center to resume my $\operatorname{RF}/\operatorname{R}$	HD Care, I will have to a	bide by the policies set
by them as a ne	w RF/RHD patient.		
Conforme by:		Certified correct by:	
	ļ	Continue control of	
	ed name and signature)	(Printed name	
(Printe	ed name and signature) nt/ Parent/ Guardian	Physician, Referring	
(Printe			




As of February 2019



Certified correct by:

(Printed name and signature) RF/RHD Coordinator, Referring RD/RHD Center

Acknowledged by:	Acknowledged by:
(Printed name and signature) BAS Head, PhilHealth Regional Office in-charge of the referring HCI (to be returned to the referring HCI five working days upon receipt of the form)	(Printed name and signature) Head/PD Coordinator, Referral PD Center











Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City Call Center (02) 441-7442 Trunkline (02) 441-7444 www.philhealth.gov.ph

Annex "H"

TRANSMITTAL FORM OF CLAIMS FOR THE OUTPATIENT BENEFITS FOR RF/RHD

	ADDRESS OF US
NAME OF CONTRACTED HEALTH CARE INSTITUTION (HCI)	ADDRESS OF HCI
,	

Instructions for filling out this Transmittal Form. Use additional sheets if necessary.

- 1. Use CAPITAL letters or UPPER CASE letters in filling out the form.
- 2. For the period of confinement, follow the format (mm/dd/yyyy).
- 3. For the Package Code, include the code for the order of tranche payment.
- 4. If the case number is available, indicate the case number in the first column.
- 5. The Remarks column may include some relevant notes which pertain to the filed claim that need to be relayed to PhilHealth.

Case Numb		Name of Patient	Period of C	Confinement	Package Code	Remarks
	* 1	(Last, First, Middle Initial, Extension)	Date admitted	Date discharged		<u> </u>
Ī	1.					
Ì	2.				<u> </u>	
_	3.		<u>_</u>			
7	4.					
<u> </u>	5.					
7]	6.		<u> </u>			
Daje: Z	7.					
	8.					
	9.			<u> </u>		-
2	10.		<u></u>			

	C.I. TICI	For Phill-lealth Use Only Initials Date
Certified correct by authorized rep	presentative of the HCI_	100 A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	Designation	Received by Local Health Insurance Office (LHIO)
Printed Name and Signature	Date signed (mm/dd/yyyy)	Received by the Benefits Administration Section (BAS):

As of February 2019

Page 1 of 1 of Annex H





10.Accr	reditation Number/Name of Accredited	Health Care Profession	al/Date Signed and Pro	ofessional Fees/Charges		
	disation number/Name of Accredited Health Care Pro	essional/Date Signed		Details		
	deation No.: 1,2,3,4,-5,6,7,8,9,					Tick this box
	JUANA DELA CRUZ, MD		No co-pay on top of	PhilHealth Benefit		if patient
	Signature Over Printed Name			or Prairieatur Benefit P		paid no
	Date Signed:					additional
Accre	ditation No.:			1		Professional
	Since the Control of		No co-pay on top of	PhilHealth Benefit	1	fee
	Signature Over Printed Name		With co-pay on top	of Philitealth Benefi P		
	Date Signed:					Tick this box
Accre	datationNo.: []]]-[[]].		No co anyon ton of	PhilHealth Benefit]	if patient
	Signature Over Printed Name			of Philhealth Benefit P		paid an
	Date Signed;	1				additional
	PART III - CERTIFICATION OF CONS				S	Professional fee
A.CERT	IFICATION OF CONSUMPTION OF BENEF					
7	PhilHealth benefit is enough to cover HCI and PF Cha	ඳුප.			- 1	Tick this box
- لــــــــــــــــــــــــــــــــــــ	no purchase of drugsymedicines, supplies, diagnosis	s, and co-pay for professional		tal Actual Charges'	¬ !	if patient has
	Total Health Care Institution Fees			000.00	- i	NO out of
	Total Professional Fees		0,0			pocket
	Grand Total		6.0	00.00	<u> </u>	payment
<u> </u>	The benefit of the member/patient was remoletely or purchases/expenses for drugs/medicines, supplies, d	ensumed oriento co-pay OR the lagrostics and others.			_	
	The total co-pay for the following are:		1			Tiple Main In acc
	Total Actual Charges'	Amount after Application of Discount (i.e., personal discount, Senior Citizen/PWO)	PhilHealth Benefit	Amount after PhilHealth Deduction		if patient has
ا م	ai l				an out of	
_< <u>₹</u>	cotal Fealth Care			Amount P Paid by (check all that applies):	-	pocket payment
~ (L	Antibution Fees				ا ان	payment
₹ Ö \	Joral Frofessional			Amount P	_	
≥ `	Teles (for accredited			Paid by (check all that applies): Member/Patient HMO		
	Prefessionals)			Others (i.e., PCSO, Promisory note, etc	د	
	b Durchases/Expenses NOT included in the Health	Care Institution Charges		·	i	
	Total cost of purchase/s for drugs/medicines and/o		le None	Total Amount P	_	
	Total cost of diagnostic/laboratory examinations pa within/outside the HCI during confinement		e None	Total Amount P	_	
	NOTE: Total Actual Charges should be based on S	tatement of Account (SOA)	J		_ i	
B.CONS	SENT TO ACCESS PATIENT RECORD/S:					
	y consent to the submission and examination of the	patient's pertinent medical re	cords for the purpose of verify	ying the veracity of this claim to effect	ł	
l hereb	nt processing of benefit payment. By hold PhilHealth or any of its officers, employees a			elative to the herein-mentioned consent		Affix
which :	have voluntarily and willingly given in connection		ent before PhilHealth.			signature of
Ciana	JUAN MASIPAG DELA CRUZ, JR. ure Over Printed Name of Member/Patient/Authorized			<u> </u>	_, I	patient
Signati			if patient/represen is unable to write,		t l	
	Date Signed: 07-29-201 month day year		right thumbmark. Representative sho	Pati-nt/		Indicate date
	nship of the representative to Spouse mber/patient: Sibling	Child Parent Others, Specify	assisted by an HCI	•		signed
Reason	of for signing on behalf of the Patient is Incaper/patient: Other Reasons	acitated).	Patient Representati	ve		
	PART IV - CERTIFICA	ATION OF CONSUMPT	ION OF HEALTH CAR	EINSTITUTION		Affix
l cer	Bify that services rendered were recorded in the part MIGUEL DELOS SANTOS	tient's chart and health care i	institution records and that ti	ne herein information given are true and	Correct.	signature of
Signati	re Over Printed Name of Authorized HCI Representati		DS OFFICER pacity/Designation	Date Signed: 0 8 0 1 2	<u> </u>	HCI representative
2.5.100			-· -			representative

Checklist of indications for oral secondary prophylaxis

Recommended Dose: (> 27 kg)

Oral Penicillin: 250 mg every 12 hours

Oral Erythromycin: 250 mg every 12 hours; if allergic to penicillin, after meals

Recommended Dose (if < 27 kg):

Oral Erythromycin: 125 mg every 12 hours; if allergic to penicillin, after meals

Oral Penicillin suspension (if available) 125 mg every 12 hours

Who can be shifted to oral prophylaxis?

	All RF	/RHD	with	moderate i	to	severe mitral	stenosis
--	--------	------	------	------------	----	---------------	----------

- ☐ All stage D patients in heart failure who cannot tolerate IM injection
- ☐ All Stage C/D RF/RHD after age 40 years recommended for life time prophylaxis
- All high risk RF/RHD after surgery- valve replacement surgery/ percutaneous mitral valvuloplasty recommended for lifetime prophylaxis
- ☐ All high risk RF/RHD after surgery-valve repair shifted to oral prophylaxis after age 40
- ☐ With known allergy to penicillin
- ☐ With malnutrition or lean muscle mass to tolerate deep IM penicillin injection






Figure 1: General Process Flow for the Provision of Care for RF/RHD (Step A: Establishing Diagnosis at the OPD/Clinic)





- Every after 6 months, submits documents for claims reimbursement Annexes C, D, E, etc.

HCP Issues RF/RHD Benzathine Injection Passport

consults with attending physician every 3 months:

Patient follows up every 21 or 28 days, as recommended, and




Checklist of services that may be outsourced

The following services can be outsourced by Level I hospitals or clinics with RF/RHD Stage A and B patients:

- ☐ OPD diagnostic tests: ASO, ESR, CRP
- ☐ OPD 2D echo
- Referral to a Cardiologist for confirmation of diagnosis and Clinical Pathway (to a Level II in Stage A and B / Level III hospital in Stage C and D)
- Referral to a Cardiologist for follow up every 6 months (to a Level 2 in Stage A and B / Level 3 hospital in Stage C and D)

Note: For patients RF/RHD Stage C and D – refer to Level III hospital with specialized cardiac care for tertiary prevention





Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre Building, 709 Shaw Boulevard, Pasig City Healthline 441-7444 www.philhealth.gov.ph



Case No. _


Annex "M - RF/RHD"

CHECKLIST FOR PATIENT TRANSFER

	Rneumatic Fever/Rneu	miauc IIcari	Discase								
HEALTH CAI	RE INSTITUTION (HCI)										
ADDRESS OF	HCI	<u> </u>									
A. PATIENT	PATIENT 1. Last Name, First Name, Middle Name, Suffix SEX Male D										
1 1 1444 - 1 1844 -	2. PhilHealth ID Number										
B. MEMBER (answer only if	swer only if										
the patient is a dependent)	2. PhilHealth ID Number			<u> </u>							
	patients* who will be transferred to be accomplished:	a referral RF	F/RHD Prov	ider, the following							
NAME OF RE	EFERRAL RF/RHD CENTER	_									
ADDRESS OF	REFERRAL RF/RHD CENTER	₹									
	Requirements	Yes O		Signature of Responsible Person							
1. Updated M	edical Abstract	☐ Yes	□ No								
2. Updated Pr	rescription for one (1) month	☐ Yes	□ No								
3. Letter of R Fellow	eferral from Attending Physician/	□ Yes	□ No	Name & signature Attending Physician							
	ntent from Patient requesting for a referral RF/RHD Provider	□ Yes	□No	Name & signature Patient/Parent/Guardian							
Certified comple	ete by:	Conforme by:	:								
L	Printed name and signature RF/RHD Coordinator Printed name and signature Patient/Parent/Guardian										
Date signed (mr	··	Date signed (1	mm/dd/yyyy)								
	Ę.										

As of February 2019

Page 1 of 1 of Annex M - RF/RHD









HOSPITAL LETTERHEAD

RHEUMATIC FEVER/ RHEUMATIC HEART DISEASE

PHILHEALTH OUTPATIENT BENEFIT PACKAGE
SYSTEMATIC CLINICAL ASSESSMENT AND FOLLOW UP FORM


LACCOMPUSH RF/RHD SUSPECT PATHWAY: LACCOMPUSH RF/RHD SUSPECT PATHWAY: Chief complaint / Clinical presentation:	PATIENT'S NAME:		DATE OF BIRTH:	REGISTRY NO.		
PHILHEALTH PRE-AUTHORIZATION APPROVAL: (Please attach photocopy) REFERRING HOSPITAL: DATE OF APPROVAL: DATE OF APPROVAL:	LAST NAME FIRST NAME	MIDDLE NAME	SEX : M F			
ADDRESS: ATTENDING CARDIOLOGIST: ACCOMPLISH RF/RHD SUSPECT PATHWAY:	PHILHEALTH PRE-AUTHORIZATION A		DATE OF	RECOMMENDATION:		
ADDRESS: ATTENDING CARDIOLOGIST:			APPROVAL:	CATEGORY		
ADDRESS: ATTENDING CARDIOLOGIST:				☐ NBB ☐ CO-PAY		
ATTENDING CARDIOLOGIST: ACCOMPLISH RF/RHD SUSPECT PATHWAY: (OPD/ PEDIA CARE)			DATE REGISTERED:			
ATTENDING CARDIOLOGIST: ACCOMPLISH RF/RHD SUSPECT PATHWAY: (OPD/ PEDIA CARE)	ADDRESS :					
Chief complaint / Clinical presentation: Date of DIAGNOSIS:						
Chief complaint / Clinical presentation: Date of DIAGNOSIS:						
Chief complaint / Clinical presentation: Date of DIAGNOSIS:						
Date of DIAGNOSIS: Rheumatic fever, definite Rheumatic fever, definite Rheumatic fever without mention of heart involvement; arthritis, acute or subaute involvement 101.0 Acute rheumatic pericarditis 101.1 Acute rheumatic endocarditis; acute rheumatic valvulitis 101.2 Acute rheumatic mycarditis 101.8 Other acute rheumatic mycarditis 101.9 Acute rheumatic mycarditis 101.9 Acute rheumatic heart disease acute rheumatic pancarditis; acute rheumatic chorea with heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heart involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 105.9 Mitral stenosis with insufficiency; mitral stenosis with insufficiency or incompetence 105.9 Mitral valve disease; mitral valve disease; mitral valve disease involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic acritic stenosis; sortic valve 106.1 Rheumatic acritic stenosis; sortic valve 106.1 Rheumatic acritic valve disease 106.9 Rheumatic involvement; heumatic valve stenosis 108.0 Disorders of both mitral and acritic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both mitral and tricuspid valves 108.3 Combined disorders of acritic ricuspid and mitral valves 109.1 PoST MITRAL VALVE REPAIR 109.2 Chronic rheumatic adherent pericarditis; rheumatic adherent pericarditis; procedure 109.2 Chronic rheumatic adherent pericarditis; procedure 109.5 MITRAL VALVE REPAIR 109.5 MITRAL VALVE REP				,		
Rheumatic fever, definite Rheumatic heart disease 10.50 Mitral stenosis; rheumatic valve obstruction 100 Rheumatic Fever without mention of heart involvement; arthritis, acute or subacute involvement 101.1 Acute rheumatic endocarditis; acute rheumatic valvulitis 101.2 Acute rheumatic endocarditis; acute rheumatic pericarditis 101.3 Other acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chart disease unspecified; active rheumatic carditis; acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heat involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea with heart involvement; rheumatic chorea NOS 105.0 Rheumatic acrdit is sufficiency or incompetence 105.8 Other mitral valve disease; mitral valve disease; mitral valve disorder NOS 106.0 Rheumatic acrtic insufficiency; acrtic regurgitation 105.2 Mitral valve ds unspecified; chronic mitral valve disorder NOS 106.0 Rheumatic acrtic insufficiency; acrtic regurgitation 106.8 Other mitral oardic stenosis with acrtic regurgitation 106.8 Other rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 106.8 Other rheumatic acrtic valve disease 106.8 Other rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 106.0 Rheumatic mitral regurgitation 106.8 Other multiple valve disease 106.9 Rheumatic diseases of the mitral regurgitation 106.8 Other multiple valve diseases 106.9 Rheumatic diseases of the endocarditis 109.0 Rheumatic mitral regurgitation 106.8 Other multiple valve diseases 106.0 Rheumatic diseases of the endocarditis 109.0 Rheumatic mitral regurgitation 106.8 Other multiple valve diseases 106.0 Rheumatic diseases of the endocarditis 109.0 Rheumatic acrtic requrgitation 106.8 Other multiple valve diseases 106.0 Rheumatic mitral regurgitation 106.8 Other rheumatic pericarditis; 109.0 Rheumatic acrtic re	•	n:	(OPD/ PEDIA CARE)	CONSULTANT		
Rheumatic heart disease 105.0 Mitral stenosis; rheumatic valve obstruction 105.1 Mitral stenosis; rheumatic rever without mention of heart involvement; arthritis, acute or subacute involvement 101.0 Acute rheumatic pericarditis 101.1 Acute rheumatic pericarditis 101.2 Acute rheumatic endocarditis; acute rheumatic aproarditis 101.2 Acute rheumatic myocarditis 101.9 Acute rheumatic heart disease, acute rheumatic pancarditis 101.9 Acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heat involvement; chorea NOS with heart 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic aortic stenosis with insufficiency; or incompetence 105.8 Other mitral valve disease; mitral valve disease; mitral valve disease of the mitral valve disorder NOS 106.0 Rheumatic aortic stenosis; aortic valve 106.0 Rheumatic aortic stenosis; aortic valve 106.0 Rheumatic aortic stenosis; aortic valve 106.0 Rheumatic aortic valve disease 106.0 Rheumatic dortic valve disease 106.0 Rheumatic aortic valve disease 106.0 Rheumatic diseases of the endocarditis 109.0 Rheumatic diseases of the endocarditis; 109.0 Rheumatic adherent pericarditis; 109.0 Rheumatic adherent pericarditis; 109.0 Rheumatic adhe	1 ————————————————————————————————————					
II. ASSESS INVOLVEMENT :	•					
100 Rheumatic Fever without mention of heart involvement; arthritis, acute or subacute involvement 101.0 Acute rheumatic periorditis 101.1 Acute rheumatic endocarditis; acute rheumatic valvulitis 101.2 Acute rheumatic myocarditis 101.8 Other acute rheumatic heart disease; acute rheumatic pancarditis 101.9 Acute rheumatic heart disease acute rheumatic carditis; acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heat involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic aortic stenosis; aortic valve 105.1 Rheumatic aortic stenosis; aortic valve 106.1 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both mitral and tricuspid valves 108.2 Disorders of both mitral and tricuspid valves 108.3 Combined disorders of aortic tricuspid and mitral valves 109.0 Rheumatic diseases of the endocarditis; rheumatic diseases of the endocarditis; rheumatic diseases of the endocarditis; rheumatic adherent pericarditis; rheumatic adherent pericarditis; rheumatic adherent pericarditis; rheumatic adherent pericarditus 109.0 Mitral valve (sease) 109.0 Rheumatic diseases of the endocarditis; rheumatic adherent pericarditis; rheumatic adherent peric			☐ 105 0 Mitral o	tenosis: rheumatic valve		
acute or subacute involvement 101.0 Acute rheumatic pericarditis 101.1 Acute rheumatic pericarditis 101.2 Acute rheumatic myocarditis 101.2 Acute rheumatic myocarditis 101.8 Other acute rheumatic heart disease; acute rheumatic carditis; acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic cheart disease unspecified; active rheumatic carditis; acute rheumatic cheart disease unspecified; active rheumatic chorea NOS with heart involvement 102.9 Rheumatic chorea with heart involvement; rheumatic chorea NOS 106.0 Rheumatic acrtic insufficiency; active regurgitation 106.1 Rheumatic acrtic insufficiency; acrtic valve 106.1 Rheumatic acrtic insufficiency; acrtic valve 106.2 Rheumatic acrtic insufficiency; acrtic valve 106.3 Rheumatic acrtic insufficiency; acrtic regurgitation 106.8 Rheumatic acrtic valve disease unspecified NOS 108.0 Disorders of both mitral and acrtic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both mitral and tricuspid valves 108.2 Disorders of both mitral and tricuspid valves 108.3 Combined disorders of acrtic tricuspid and mitral valves 109.1 Rheumatic diseases on the acrtic and tricuspid valves 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericarditus; rheumatic adherent pericardit		mention of heart involvement : arthritis				
101.0 Acute rheumatic pericarditis 101.1 Acute rheumatic pericarditis 101.1 Acute rheumatic endocarditis; acute rheumatic valvulitis 101.2 Acute rheumatic endocarditis; acute rheumatic pericarditis 101.8 Other acute rheumatic heart disease; acute rheumatic pancarditis 101.9 Acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heat disease unspecified; active rheumatic carditis; acute rheumatic chorea with heat involvement; rheumatic chorea NOS 102.0 Rheumatic chorea without heart involvement; rheumatic chorea NOS 105.0 Rheumatic aortic stenosis; acute valve 105.9 Rheumatic aortic stenosis; acute valve 106.1 Rheumatic aortic insufficiency; acritic regurgitation 106.2 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Disorders of both mitral and acritic valves; whether specified as rheumatic in etiology or NOS 108.0 Multiple valve disease unspecified 109.0 Rheumatic inseases of the endocarditis 109.1 Rheumatic diseases of the endocarditis; rheumatic adherent pericarditum 109.2 Chronic rheumatic valve disease unspecified 109.0 Rheumatic adherent pericarditum 109.0 Rheumatic adherent pericarditus; rheumatic adherent pericarditus; rheumatic adherent pericarditus 109.2 Chronic rheumatic pericarditus; rheumatic adherent pericarditus 109.0 Rheuma	1		☐ 105.1 Rheum	atic mitral insufficiency;		
101.2 Acute rheumatic myocarditis 101.8 Other acute rheumatic heart disease; acute rheumatic pancarditis 201.8 Other acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic heart disease 102.0 Rheumatic chorea with heat involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic acrtic stenosis; active regurgitation 106.1 Rheumatic acrtic insufficiency; acrtic regurgitation 106.2 Rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 108.0 Disorders of both mitral and acrtic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 109.0 Rheumatic diseases of the endocarditis 109.1 Rheumatic diseases of the endocarditis; rheumatic diseases of the endocarditis; rheumatic adherent pericarditis; rheumatic adherent peri	☐ 101.0 Acute rheumatic pericardi	tis				
101.8 Other acute rheumatic heart disease; acute rheumatic pancarditis 101.9 Acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heat involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea with heart involvement; rheumatic chorea NOS 106.0 Rheumatic acrtic involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic acrtic involvement 106.1 Rheumatic acrtic involvement 106.2 Rheumatic acrtic involvement 106.2 Rheumatic acrtic involvement 106.2 Rheumatic acrtic involvement 106.2 Rheumatic acrtic valve disease 106.9 Rheumatic valve disease 106.9 Rheumatic valve disease 106.9 Rheumatic val	☐ 101.1 Acute rheumatic endocard	itis; acute rheumatic valvulitis				
101. 9 Acute rheumatic heart disease unspecified; active rheumatic carditis; acute rheumatic chorea with heart disease 102.0 Rheumatic chorea with heart involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic aortic stenosis; aortic valve 106.1 Rheumatic aortic insufficiency; aortic regurgitation 106.8 Cheumatic aortic stenosis with aortic regurgitation 106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.0 Disorders of both mitral and tricuspid valves 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both mitral and tricuspid valves 108.2 Disorders of both aortic and tricuspid valves 108.3 Combined disorders of aortic tricuspid and mitral valves 108.0 Disorders of both mitral and tricuspid valves 108.1 Rheumatic diseases of the endocardium; chronic rheumatic valvelitis/ endocarditis; rheumatic adherent pericarditis; rheumatic adherent pericardium 108.0 Disorders of sortic tricuspid and mitral valves 109.0 Rheumatic adherent pericardium 109.0 Rheumatic adherent pericardium 109.0 Reptact						
acute rheumatic heart disease 102.0 Rheumatic chorea with heat involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 106.0 Rheumatic acrtic stenosis; acrtic valve 106.1 Rheumatic acrtic insufficiency; acrtic regurgitation 106.2 Rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 106.0 Rheumatic acrtic valve 106.0 R	□ 101.8 Other acute rheumatic he	art disease; acute rheumatic pancarditis				
102.0 Rheumatic chorea with heat involvement; chorea NOS with heart involvement 102.9 Rheumatic chorea without heart involvement; rheumatic chorea NOS 105.9 Mitral valve disorder NOS 106.0 Rheumatic acrtic stenosis; acrtic valve 106.1 Rheumatic acrtic insufficiency; acrtic regurgitation 106.2 Rheumatic acrtic valve disease 106.9 Rheumatic acrtic valve disease 108.0 Disorders of both mitral and acrtic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both acrtic and tricuspid valves 108.2 Disorders of both acrtic and tricuspid valves 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvelitis/ endocarditis 109.2 Chronic rheumatic pericarditis 109.2 Chronic rheumatic per				responsible to the second of t		
involvement 102.9 Rheumatic chorea without heart Involvement; rheumatic chorea NOS 105.9 Mitral valve disorder NOS 106.0 Rheumatic aortic stenosis; aortic valve 106.1 Rheumatic aortic insufficiency; aortic regurgitation 106.2 Rheumatic aortic stenosis with aortic regurgitation 106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve			failure			
106.0 Rheumatic aortic stenosis; aortic valve 106.1 Rheumatic aortic insufficiency; aortic regurgitation 106.2 Rheumatic aortic stenosis with aortic regurgitation 106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease unspecified NOS 108.0 Other multiple valve disease unspecified NOS 108.0 Other multiple valve diseases 108.0 Multiple valve disease unspecified rheumatic in etiology or NOS 109.0 Rheumatic myocarditis 109.0 Rheumatic myocarditis 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valves 108.3 Combined disorders of aortic tricuspid valves 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic pericardium 109.3 Combined disorders of aortic tricuspid and mitral valves 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.0 Rheumatic aortic valve disease 108.8 Other multiple valve disease 108.0 Multiple valve disease 108.0 Multiple valve disease 109.0 Rheumatic aortic valve 109.0 Rheumatic aortic valve disease 109.0 Rheumatic aortic valve disease 109.0 Rheumatic aortic valve 109.0 Rheumatic aortic valve 109.0 Rheumatic aortic valve 109.0 Rheumati	involvement					
106.1 Rheumatic aortic insufficiency; aortic regurgitation 106.2 Rheumatic aortic stenosis with aortic regurgitation 106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.0 Multiple valve disease unspecified rheumatic in etiology or NOS 109.0 Rheumatic myocarditis 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvelitis/ endocarditis 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvelitis/ endocarditis 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Other of procedure STATUS 109.5 Mitral valve Replacement 109.5 Mitr	☐ 102.9 Rheumatic chorea without	heart involvement; rheumatic chorea NOS				
regurgitation 106.2 Rheumatic aortic stenosis with aortic regurgitation 106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.0 Multiple valve disease unspecified rheumatic in etiology or NOS 109.0 Rheumatic myocarditis 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvelitis/ endocarditis 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic valvulitis/ endocarditis 1						
106.2 Rheumatic aortic stenosis with aortic regurgitation 106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.0 Multiple valve disease unspecified rheumatic in etiology or NOS 109.0 Rheumatic myocarditis 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvulitis/ endocardium; chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericardium 108.3 Combined disorders of aortic tricuspid and mitral valves 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic adherent pericardium 109.2 Chronic rheumatic adherent pericardium 109.3 POST MITRAL VALVE REPAIR GOOD REFER TO VALVE 109.5 MITRAL VALVE REPLACEMENT REFER TO VALVE TEAM						
106.8 Other rheumatic aortic valve disease 106.9 Rheumatic aortic valve disease 108.0 Pheumatic aortic valve diseases 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 109.0 Rheumatic myocarditis 109.1 Rheumatic diseases of the 108.2 Disorders of both aortic and tricuspid valves endocardium; chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic pericardium 109.2 Chronic rheumatic adherent pericardium 109.2 POST MITRAL VALVE REPAIR GOOD REFER TO VALVE 109.5 MITRAL VALVE REPLACEMENT REFER TO VALVE TEAM						
106.9 Rheumatic aortic valve disease unspecified NOS 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both aortic and tricuspid valves 108.2 Disorders of both aortic and tricuspid valves 108.3 Combined disorders of aortic tricuspid and mitral valves 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium 109.2 Chronic rheumatic pericar						
Unspecified NOS ☐ 107.0 Tricuspid stenosis; Rheumatic valve stenosis ☐ 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS ☐ 108.1 Disorders of both mitral and tricuspid valves ☐ 108.2 Disorders of both aortic and tricuspid valves ☐ 108.3 Combined disorders of aortic tricuspid and mitral valves ☐ 108.3 Combined disorders of aortic tricuspid and mitral valves ☐ 109.2 Chronic rheumatic valvulitis/ endocarditis ☐ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium III. CHECK IF PROCEDURE/ INTERVENTION DONE ☐ 1 POST MITRAL VALVE REPAIR ☐ 2 POST MITRAL VALVE REPLACEMENT ☐ 3 POST AORTIC VALVE REPLACEMENT ☐ 3 POST AORTIC VALVE REPLACEMENT ☐ 4 POST MITRAL VALVULOPLASTY ☐ 1 POST MITRAL VA						
□ 107.0 Tricuspid stenosis; Rheumatic valve stenosis □ 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS □ 108.1 Disorders of both mitral and tricuspid valves □ 108.2 Disorders of both aortic and tricuspid valves □ 108.3 Combined disorders of aortic tricuspid and mitral valves □ 108.3 Combined disorders of aortic tricuspid and mitral valves □ 108.6 Other multiple valve diseases □ 108.0 Multiple valve disease unspecified as 109.0 Rheumatic myocarditis □ 109.0 Rheumatic diseases of the endocardium; chronic rheumatic valvulitis/ endocardium; chronic rheumatic valvulitis/ endocarditis □ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium III. CHECK IF PROCEDURE/ INTERVENTION DONE □ 1 POST MITRAL VALVE REPAIR □ 2 POST MITRAL VALVE REPAIR □ 3 POST AORTIC VALVE REPLACEMENT □ 3 POST AORTIC VALVE REPLACEMENT □ 4 POST MITRAL VALVULOPLASTY □ 108.8 Other multiple valve diseases □ 108.0 Multiple valve disease unspecified as 109.0 Multiple valve disease unspecified 109.0 Multiple valve disease unspecified 109.0 Multiple valve disease unspecified 109.0 Rheumatic myocarditis 109.0 Rheumatic diseases of the endocardium; chronic rheumatic valvulitis/ endocardi						
□ 108.0 Disorders of both mitral and aortic valves; whether specified as rheumatic in etiology or NOS □ 108.1 Disorders of both mitral and tricuspid valves □ 108.2 Disorders of both aortic and tricuspid valves □ 108.3 Combined disorders of aortic tricuspid and mitral valves □ 108.3 Combined disorders of aortic tricuspid and mitral valves □ 108.4 Chronic rheumatic valvulitis/ endocarditis □ 109.5 Chronic rheumatic pericarditis; rheumatic adherent pericardium □ 108.5 Combined disorders of aortic tricuspid and mitral valves □ 108.6 Multiple valve disease unspecified □ 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvulitis/ endocarditis □ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium □ 108.6 Multiple valve disease unspecified □ 109.0 Rheumatic myocarditis □ 109.1 Rheumatic diseases of the endocardium; chronic rheumatic valvulitis/ endocarditis □ 109.2 Chronic rheumatic adherent pericardium □ 109.2 Chronic rheumatic adherent pericardium □ 109.2 Chronic rheumatic □ 109.3 Chronic r	☐ 107.0 Tricusnid stenosis: Rheum	natic valve stenosis				
rheumatic in etiology or NOS 108.1 Disorders of both mitral and tricuspid valves 108.2 Disorders of both aortic and tricuspid valves 108.3 Combined disorders of aortic tricuspid and mitral valves 108.3 Combined disorders of aortic tricuspid and mitral valves 109.2 Chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium III. CHECK IF PROCEDURE/ INTERVENTION DONE 109.0 Rheumatic myocarditis endocardium; chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium Date of procedure 109.0 Rheumatic myocarditis 109.1 Rheumatic myocarditis 109.2 Chronic rheumatic 109.3 Chronic rheumati			☐ 108.0 Multip	le valve disease unspecified		
108.2 Disorders of both aortic and tricuspid valves endocardium; chronic rheumatic valvulitis/ endocarditis 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium	rheumatic in etiology or N	105				
□ 108.3 Combined disorders of aortic tricuspid and mitral valves □ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium □ 1 POST MITRAL VALVE REPAIR □ 1 POST MITRAL VALVE REPLACEMENT □ 3 POST AORTIC VALVE REPLACEMENT □ 4 POST MITRAL VALVULOPLASTY □ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium □ 3 Date of procedure □ 3 GOOD □ REFER TO VALVE □ TEAM □ TEAM						
☐ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium III. CHECK IF PROCEDURE/ INTERVENTION DONE ☐ 1 POST MITRAL VALVE REPAIR ☐ 2 POST MITRAL VALVE REPLACEMENT ☐ 3 POST AORTIC VALVE REPLACEMENT ☐ 4 POST MITRAL VALVULOPLASTY ☐ 109.2 Chronic rheumatic pericarditis; rheumatic adherent pericardium ☐ 3 Date of procedure ☐ GOOD ☐ REFER TO VALVE ☐ TEAM						
Theumatic adherent pericardium III. CHECK IF PROCEDURE/ INTERVENTION DONE Date of procedure STATUS POST MITRAL VALVE REPAIR POST MITRAL VALVE REPLACEMENT OST AORTIC VALVE REPLACEMENT OST MITRAL VALVULOPLASTY	LI 108.3 Combined disorders of ao.	ruc tricuspiù and mitrai valves				
☐ 1 POST MITRAL VALVE REPAIR ☐ 2 POST MITRAL VALVE REPLACEMENT ☐ 3 POST AORTIC VALVE REPLACEMENT ☐ 4 POST MITRAL VALVULOPLASTY ☐ 3 POST MITRAL VALVULOPLASTY ☐ 4 POST MITRAL VALVULOPLASTY ☐ 5 POST MITRAL VALVULOPLASTY		_				
☐ 2 POST MITRAL VALVE REPLACEMENT ☐ 3 POST AORTIC VALVE REPLACEMENT ☐ 4 POST MITRAL VALVULOPLASTY ☐ 12 POST MITRAL VALVULOPLASTY ☐ 13 POST MITRAL VALVULOPLASTY ☐ 14 POST MITRAL VALVULOPLASTY ☐ 17 POST MITRAL VALVULOPLASTY	III. CHECK IF PROCEDURE/ INTERVENTION	DONE	Date of procedure	STATUS		
☐ 2 POST MITRAL VALVE REPLACEMENT ☐ 3 POST AORTIC VALVE REPLACEMENT ☐ 4 POST MITRAL VALVULOPLASTY ☐ 12 POST MITRAL VALVULOPLASTY ☐ 13 POST MITRAL VALVULOPLASTY ☐ 14 POST MITRAL VALVULOPLASTY ☐ 17 POST MITRAL VALVULOPLASTY	TIE 1 DOCT MITDAL VALVE DEDAID			GOOD		
TEAM OST MITRAL VALVULOPLASTY TEAM		MENT				
OST MITRAL VALVULOPLASTY			1	i e		
d _a □ 3/5 DTHERS				LEWIAI		
	d ∐'S OTHERS					
		<u> </u>	<u> </u>			

RHEUMATIC	FEVER	RHEUMATIC HEART		
DISEASE				
PHILHEALTH OUTPA				
		TENT AND FOLLOW UP FORM		1
PATIENT'S NAME: (p	age 2)	•	DATE OF BIRTH	H: PHILHEALTH ID NO.
			SEX: M 🗆 F	一
_	- -		_	
LAST NAME			1	
III. CHECK ANTISTRI	PTOLYSIN -O	(ASO)	DATE	
	: START PRII	MARY PROPHYLAXIS		
IV. CHOOSE SECONE	DARY PROPHY	LAXIS: CHECK ALGORITHM	DATE:	OTHER REMARKS:
		dose and duration)		
☐ IM BPN 1.2		ORAL ERYTHROMYCIN ORAL PENICILLIN		RELEVANT HISTORY
	L _	1 ONAL I LAIGILLIA		
		☐ 21 days ☐ DAILY (ORAL)		
] age 18 yrs	age 21 yrs old age 40		PHYSICAL EXAM :
JUSTIFICATION I	F OR A I	•		
JOSTITICATION	· UNAL			
V. CHECK FOR DISE	ASE ACTIVITY	:	DATE	OTHER REMARKS
CRC · Hah	Het	WBC: Segmenters		
ESR				
MEDICATION				
VI CHECK HEADT EA	TITIDE ELIMO	TIONAL CLASS : I II III	VII. DATE	
I IV	HEORE FORC		DISCHARGE F	PLAN:
Meds: 1			ADN	
2				FOLLOW UP
3 4			Dat	te:
"				
LABORATORY EXA	MINATION			
2D ECHO FINDINGS Y	EAR 1		Date	
VALVE INVOLVEMENT	Γ:	STAGE: (Encircle)	ASO	
LV SIZE :		A B C D	ESR	
		RECOMMENDATION:	CRP	
EF:		☐ SECONDARY PREVENTION	Others	-
FUNCTIONAL CLASS:		ONLY REFER TO VALVE TEAM IF	CBC	
	l	CLASS C/D INVOLVEMENT		
ECHO FINDINGS YEAR	<u> </u>	STAGE: (Encircle)	Date	
VALVE INVOLVEMENT		давс о	ASO	
11/15/75 :	Ž	BECOMMENDATION:		
LV SIZE :	بت محک [ران	RECOMMENDATION: SECONDARY PREVENTION	555	
EF:	TER PY Date:	ONLY	ESR CRP	
FUNCTIONAL CLASS	F00	1 1 - 11-11-11-11-11-11-11-11-11-11-11-1		
	8235	CLASS C / D INVOLVEMENT	Others	
	≥ 3	.	СВС	
1	Z.			
				
	3			-

_														
FOLIO FINISHE	- VE								 D=1					
ECHO FINDINGS YEAR 3 VALVE INVOLVEMENT:				STAGE	: (Enci	rcle)			Date					
					A B C D									
LV SIZE :				RECON	/MEND	ATION:			ESR		_			
EF:					SECO	NDARY PR	REVENTION	1	CRP					
FUNCTIONAL C	FUNCTIONAL CLASS:		_	ONLY		'E TEAM IF		Others				_		
							OLVEMEN		СВС					
ECHO FINDING	S YEAR 4								Date					
VALVE INVOLV					: (Enci									
LV SIZE :				_ A	В	C D			ASO		1			
1 14 3121				RECON	MEND	ATION:			ESR CRP					
EF : FUNCTIONAL C	1 400 .				SECO ONLY		REVENTION	1	CRP					
FUNCTIONALC	LA33 ;						'E TEAM IF	•	Others CBC					
					CLASS C / D INVOLVEMENT									
ECHO FINDING	S YEAR 5			STAGE	: (Enci	rcle)			Date	-				
VALVE INVOLV	EMENT:			A	В	C D			ASO					
LV SIZE :				RECON	/MEND	ATION:								
				☐ SECONDARY PREVENTION					ESR CRP					
FUNCTIONAL C	LASS :				ONLY REFE		E TEAM IF	:	Others					
							OLVEMEN		Others CBC					
BENZATHINE PER	NICILLIN CO	OMP	LIANC	E SUMMA							x 100 :	<u> </u>		
YEAR	_		YEA	R 1	1 YEAR 2					Total scheduled q 21 days YEAR 3				
ICAN			ILA		1 YEAR 2									
% Compliance							!							
Actual/ Expected							İ							
Signature					-									
							!						-	
Date			YEA	R 4	_		YEAR 5			COMPLIANCE RATING			·	
		1					_		_		ELLEENT	100%		
% Compliance Actual/										S SAT	SFACTORY DD	90% >80%		
Expected Signature				_			-			F FA!	R	<80% <50%		
SiRuarme									, ,	р ро	OR	<50%		
VII. IMMUNI	ZATION !	<u> </u> ∤IST	ORY	0		<u>.</u>								
Heb B Booster				7		PCV Bo	oster (IPD)							
DPT adult (afte	er 7)			*		Pneum	ococcal							
MMR booster		, di		Flu vac	cine				-					
Varicella Boost	ter				1	Others	<u>-</u>							
DENTAL CLEAR	RANCE	7		\$	1	· · · · · · · · · · · · · · · · · · ·	\							
		Ì	2	, 3/	1									
												_		
		Į		2										

()

Signature: DATE: TIME:	
FOR STAGE C-D: VALVE TEAM RECOMMENDATIONS	OTHER REMARKS:
Signature : DATE: TIME :	
FOR STAGE C-D: VALVE TEAM RECOMMENDATIONS REPRESENTATION	OTHER REMARKS :
Signature: DATE: TIME:	
SURGERY/ INTERVENTION REFERRAL	Social Service Referral
	STATUS
	Social Service Approval:
	STATUS
	Surgery Pre-op Presentation:
	STATUS
	Tentative Date of Admission
	SIAIUS
Date TIME	



HOSPITAL LETTERHEAD

NATIONAL RF/RHD REGISTRY DATA SHEET

I.	DEMOGRAPI	HICS		۵	
INST	TUTION CODE:		DATE RE	GISTERED :	
PATI	ENT CODE:		YEAR OF		CATEGORY:
	ON (Please encircle)				□ OPD
l	CAR NCR	ı		_	☐ IN-PATIENT
l	1 111	IVA	SEX:		□ ER
ļ	VB V	VI I	□ F	EMALE	☐ PRIVATE CLINIC
١	∕II VIII	ıx	□ N	1ALE	☐ OTHERS
,	K XI	XII			_ 55
Α	RMM				
I	I. DIAGNOSIS				
DATE	OF DIAGNOSIS:				
	Rheumatic Fever		□ Rh	eumatic Heart Diseas	se
Ci	IECK SYMPTOMS O	N INITIAL PRESENTATION		IF RHD, CHECK SI	GNS/ SYMPTOMS
MAJ	OR	MINOR			
	arditis	☐ Fever			
	olyarthritis/	☐ Arthralgia		t pain	☐ Tachypnea
1	onoarthritis/	☐ ECG: prolonged PR		ycardia	☐ Easy Fatigabilty
	olyarthralgia	Interval/ 1 st degree AV block	☐ Dysp		☐ Syncope☐ Exercise intolerance
□ Su	ıbcutaneous	□ ESRincreased		tation optysis	☐ Nocturnal dyspnea
n r.	nodules ythema marginatum	normal		dal edema	☐ Others
□ Er □ Ch	•	☐ CRP increased	п прес	dai ederiia	- Uniers
	lorea	normal			
		☐ ASO positive			
		normal			
ı	II. ASSESS INVO	LVEMENT (encircle the number if a	pplicable):	W And	The second secon
A. V/	ALVES/ STRUCTURES				
		ver without mention of heart			Rheumatic valve obstruction
		tis, acute or subacute involvement	0		al insufficiency; Rheumatic Mitral
	101.0 Acute rheum	•] _	regurgitation	
	valvulitis	atic endocarditis; acute rheumatic		with	with insufficiency; mitral stenosis
	101.2 Acute rheuma	atic myocarditis		insufficiency or incom	petence
		heumatic heart disease; Acute			ve disease; Mitral valve failure
_	rheumatic pancardi			105. 9 Mitral valve ds	unspecified; Chronic mitral valve
	101. 9 Acute rheum	atic heart disease unspecified; Active		Disorder NOS	
		Acute rheumatic heart disease			ic stenosis; aortic valve
		orea with heat involvement; chorea		106.1 Rheumatic aorti	ic insufficiency; aortic
	NOS with heart invo	orea without heart involvement;		Regurgitation 106.2 Rheumatic aorti	ic stenosis with aortic
	Rheumatic chorea	uos III.		regurgitation	ic steriosis with dorth
		nosis; Rheumatic valve stenosis	PY Date	106.8 Other rheumatic	c aortic valve disease
	•	ooth mitral and aortic valves; whether			ic valve disease unspecified NOS
1		itic in etiology or NOS		108.0 Multiple valve d	lisease unspecified
	•	ooth mitral and tricuspid valves 🍃	(2) p	108.8 Other multiple v	
		ooth aortic and tricuspid valves 📗 🗜	127	109.0 Rheumatic myo	
	108.3 Combined dis	orders of aortic, tricuspid and mitral	ا ان ا		ases of the endocardium; Chronic
	valves	ļ	22	rheumatic Valvulitis/ e	
				adherent pericardium	itic pericarditis; Rheumatic
			I	annerent berkaraian	

R CHEC	CK FCHOCAR	DIOGRAPHIC CLASSIF	ΙζΔΤίΩΝ ΒΥ	'VΔIVF I	NVOI VEMEN	T (Fnci	rcle annronriat	e Sta	uge)	
	TAGE	DEFINITION		VALVE	TO COLUMNICA		CRIPTION	,. 5(2	'6~ <i>1</i>	
	A	At risk	Patients	atients with risk factors for development of valvular heart disease.						
	В		Progressive Patients with progressive VHD (mild-moderate severity and asymptomatic)							
	C	Asymptomatic severe	Asympton C1 : Asym compens	Asymptomatic patient who have the criteria for severe VHD C1 : Asymptomatic patients with severe VHD whom the left/right ventricle remains compensated C2 : Asymptomatic patients with severe VHD with decompensation of the left / right						
			ventricle	•	•				and of the left y fight	
* 45.40	D	Symptomatic severe				1,000	as a result of VH	D		
ĪV.	RECON	/IMENDATION (base	d on above	e Echoca						
	STAGE A AN	D B : SECONDARY PROPH	IYLAXIS ONLY	(□ STAG	E D : SE		HYLA	ARY PROPHYLAXIS XIS AND MEDICAL E	
ĮV.	MANA	GEMENT		** *** *** *** *** *** *** *** *** ***	740.00		The second secon	Į. i.		
	ONDARY PRO		COMPLIANC	E ; (Tick v	/early)		<u> </u>	IF (COMPLIANCE IS FAIR	
-	OF PROPHYL			POOR	FAIR	GOOD	EXCELLENT		ECK REASON/S:	
1.,	ORAL DAILY		Year 1						DIFFICULTY TO TRAVEL	
ᆔ	o PCN		Year 2						TO HEALTH CARE	
	o ERYTHRON	AYCIN	Year 3						INSTITUTION	
	o OTHERS		Year 4				_		DRUG NOT AVAILABLE	
	_		Year 5		_				OTHERS	
П	IM BPN		Year 6				<u> </u>			
	o every 21 D	Pays *	Year 7 Year 8							
	o every 28 D		Year 9							
	,	,	Year 10		 					
2. DUR	ATION				! <u></u> !			'		
	5 years		Compliance f	or IM BPN	/ year					
	Until age 21				Every 21 days		Every 28 days			
	Until age 25		POOR (< 50		< 12		<7			
	Until age 40		FAIR (50 – 8		13 – 14	ļ	8-10			
	For life		GOOD (> 80 EXCELLENT		15 -16 17	11-12				
			EXCELLENT_	(100%)		I	1.5			
B. TER	TIARY PROP	HYLAXIS:			C. IF PROCEI	OURE/	INTERVENTION	N DO	NE TICK/ CHECK :	
CHE	CK RECOMME	NDATION (by the VALV	E TEAM)		☐ POST MIT	ral va	LVE REPAIR			
	VALVE REPL				☐ POST MI	TRAL VA	LVE REPLACEME	ENT		
	o Mitral Val	ve Replacement			1		LVE REPAIR			
1		ve Replacement			□ POST AO	RTIC VA	LVE REPLACEME	NT		
		d Aortic Valve Replaceme					LVULOPLASTY			
		AIR (Specify valve)			VALVE REPAIR			
	Percutaneo	us Mitral Balloon Valvot	omy		ู่ □ OTHERS				_	
		O VALVE TEAM:	<u> </u>	1/2						
VALVE	TEAW REPRE	SENTATIVE (Print Name	/ /	w,≱						
TENTA	TIVE SCHED	ULE :	Ü	P P	STATUS AFT			_		
			(v)	$\bar{\mathbf{Q}}$ 1	CLEARED			لم	ul locion)	
				C) co			EARLY (If with re			
DATE	OF PROCEDI	JRE:		3			NEEDED			
	IDING CARD	IOLOGIST / RFRHD Co	ordinator		Physician -o	n duty	(Print name)			
(Fillic	. namej		<u> </u>		 					

HOSPITAL

NUMBER

BIRTHDATE

CLINICAL PATHWAY THE RHEUMATIC FEVER SUSPECT

HOSPITAL	NAME
----------	------

DEPARTMENT OF

CLINICAL PATHWAY -THE RHEUMATIC FEVER SUSPECT (SYSTEMATIC CLINICAL AND MANAGEMENT PATHWAY)

INCLUSION CRITERIA:

- Age 3 -25 years of age
- Chief complaint of any of the following:
 - a) Recurrent Strep throat infection
 - b) Joint pain/swelling with or without fever of ≤ 2 weeks
 - c) New unexplained murmur
 - d) Heart failure: fast heart rate ± tachypnea
 - e) Motor instability/movement disorder

EXCLUSION CRITERIA:

PATIENT'S NAME:

- Presence of any focus of infection by Chest x-ray and/or urinalysis
- Proven diagnosis of other immunologic disease, ie. SLE, Rheumatoid Arthritis of any type

T A OPT NAMED TO THE OPT	NAME MIDDLE NAME M F		
LAST NAME FIRST	NAME MIDDLE NAME M F	_	
DAY 1: Pathway Activated: Date:	Time:OPD EMERGENO	Y ROOM IN-PA	TIENT [
PHYSICIAN'S NOTES	PHYSICIAN'S ORDERS	VARIANCE	SIGN
Check subjective CHIEF	I. APPLY JONES CRITERIA AS FOLLOWS:		
complaints/symptoms:	A. Check / qualify symptoms at least any one of the		
	following MAJOR MANIFESTATIONS		
	1. IF with JOINT PAINS, CHECK IF at least		
	ANY TWO of the following is true:	A_B_C_D_	
	☐ Migratory in nature	A_B_C_D_ A_B_C_D_	
Vital signs:	☐ Large joints, asymmetrical	A_B_C_D_	
BP: HR: RR: Temp: Ht: Wt:	☐ With tenderness, arthralgia	A_B_C_D_	
Temp: Ht: Wt: BSA: BMI:	☐ Pain on locomotion		1
O2 sat:	☐ Instantaneous relief with antipyretic/anti-	A_B_C_D_	
02 sat	inflammatory drugs	A_B_C_D_	
Latest Clinical Findings:	☐ No joint deformity		
Skin:	O HE M CARDITIS shook if ANY ONE of		
palepinkjaundice	2. IF with CARDITIS, check if ANY ONE of the following is present:	A B C D	
cyanotic		A_B_C_D_ A_B_C_D_	
·	Chest pain	A_B_C_D_ A_B_C_D_	
Pupils (size/reactivity):	☐ Tachypnea for age	A_B_C_D_	ı
Conjunctivae (pink / pale)	☐ Tachycardia for age ☐ Sleeping HR >100/min	A_B_C_D_	
Chest expansion:		A_B_C_D_ A_B_C_D_	
Lung (breath sounds):	1	A_B_C_D_	
Lung (breath sounds).			
Heart (murmurs):	☐ PE: with murmur :		
Abdomen:			
Liver edge:	100.		
Peripheral and Central	F with ERYTHYMATOUS, NON-	is	
pulses:	PRURITIC RASH, Check if ANY ONE of	A_B_C_D_	
Extremities: Warm / cold	the following is true:		
CRT: <2sec > 2 sec C	the following is true: Transient, serpiginous with irregular margins and pale center	A_B_C_D_	
Neuro exam:	margins and pale center		
 \sigma(☐ More on trunks and limbs	A_B_C_D_	
	Worsens with application of heat and	A_B_C_D_	1
	disappears	A B C D	
ĺ	□ With cold exposure	A_B_C_D_	1

Unaffected by anti-inflammatory drugs

HOSPITAL NAME

DEPARTMENT OF _

PATIENT'S NAME:

CLINICAL PATHWAY -THE RHEUMATIC FEVER SUSPECT (SYSTEMATIC CLINICAL AND MANAGEMENT PATHWAY) BIRTHDATE HOSPITAL

					NUMBER	
LAST NAME	FIRST NAME	MIDDLE NAME	M	<u>F</u>		
	DAY 1 : I		ge 2)	***		ares.
PHYSICIAN'S NOTE		HYSICIAN'S ORDERS		VARI	IANCE	SIGN
PHYSICIAN'S NOTE	4. IF with CHOI follow □ In gt □ "S □ D □ CI sti □ St ha 5. IF with NOD follow	h unusual movement disorder REA; Check if ANY ONE of ing is present: itial clumsiness, emotional labitimacing of face it Vitus dance" during movem isappears at rest or during slee heck for handwriting irregular rokes retch out both hands and check and falls versus the other hand the PEA SIZED SUBCUTANE ULES, check if ANY ONE oring is true: ard and painless	the ility,or ent p ity with ck if one	A B A B A B A B	CD CD CD CD CD	SIGN
NURSING ASSESSMENT Braden Risk Score:	□ O sp T: □ La	occur over extensor surfaces of oine, scapulae and scalp asts for weeks	joints,		_CD _CD	
		any one of the following as		A 79		
General Pain Assessment:		NIFESTATION/S:	T.S.		_CD _CD	
NIPS – FACES:	I	xplained fever at least 3 -5 day tralgia , recurrent or	/ S	A B_	_CD _CD	
Fall Risk Score:	☐ Loss	of weight				
3/2/19	 II. Request : CBC Anti ESR ECC 2DE □ Ches □ Anti 	for the following Laboratory: with platelet -Streptolysin O (ASO) titer , CRP		A B A B A B A B A B	_CD _CD _CD _CD _CD _CD _CD	
MASTER COPY DO: M/S Date:	ANY of the follow pathway Any (1-5) Any 5) Pand	One (1) Major Manifestation LUS any two (2) minor criteria	ns in IA in IA (1- in IB	A B_	_C_D_ _C_D_ _C_D_	

HOSPITAL NAME

DEPARTMENT OF _

CLINICAL PATHWAY -THE RHEUMATIC FEVER SUSPECT (SYSTEMATIC CLINICAL AND MANAGEMENT PATHWAY)

PATIENT'S NAME:		BIRTHI	DATE	HOSPITA NUMBER		
LAST NAME FIRST NAME MIDDLE NAME			M F		NUMBER	
DAY 1: Date:	(page 3)					
PHYSICIAN'S NOTES	PHYSICIAN'S ORDERS	Ĩ	VARI	ANCE	SIGN	
	IV. DIAGNOSE AS RHEUMATIC FESUSPECT If ANY of the following is true (Procedischarge planning) □ Symptoms/ clinical presentations completely fulfill criteria as Major Manifestation □ Only minor manifestations are proceeded. 1. GIVE PRIMARY PROPHYLAXIS ASO +) □ Single dose deep IM Benzathine. □ Oral PCN VK 50 mg/kg/day for Dose: □ Erythromycin if allergic to PCN	eed to s do not r resent S (For Penicillin r 10 days:	AB AB AB	.C_D_ .C_D_ .C_D_ .C_D_		
	for 10 days: 2. Give anti-inflammatory If ACTIVE 4 weeks: ASA 60-70 mg/kg/d max 3gms/ meals IF ARTHRITIS is major s Dose: Prednisone 1-2 mg/kg/day for 4 then Taper in 2 weeks: Dose:	E for 'day After ymptom:	A B	.CD _CD		
STER OPY Jaie: 3/2/19	3. Treat CONGESTIVE HEART FAIr present Digoxin: Furosemide: Vasodilator (Captopril) Others:		A B A B	_CD _CD _CD _CD		
DC: MAR	VI. Check if consults with following servineeded (indicate name of specialist): Nephrology Neurology Hematology Rheumatology Others		A B A B A B	C_D_ C_D_ C_D_ C_D_ C_D_ C_D_		

HOSPITAL NAME

DEPARTMENT OF _

CLINICAL PATHWAY -THE RHEUMATIC FEVER SUSPECT (SYSTEMATIC CLINICAL AND MANAGEMENT PATHWAY)

PATIENT'S NAME:	B.	IRTHDATE	HOSPITAL NUMBER
LAST NAME FIRST	NAME MIDDLE NAME M	F	TAUMDISK
DAY 1 : Date:	(page 3)		
PHYSICIAN'S NOTES	PHYSICIAN'S ORDERS		IANCE SIGN
	VII. Diet/Nutrition:	AB_	_CD
	VIII. Safety (see Nursing and Safety Protocol)	A B	_CD
	IX. Provide Psychosocial/Spiritual support to: Therapy appropriate for age Inquire about the need for psychologic evaluation (CHEERS protocol)	cal A_B_	_CD
	 X. Patient/Family Education: Disease process, course of disease Explain pathophysiology as non-infect Discuss Clinical Pathway with Family XI.PARENTS/GUARDIAN UNDERSTOOD VERBALIZED, CONSENTED AND 	AB_ AB	_CD _CD _CD
	SIGNED THE RF CARE PLAN Yes No		_CD _CD
MASTER COPY Sonate: 32/6	XII. OUTCOME GOALS: Utial signs stable Admit if in heart failure Or unable to ambulate or Fever more than 7days Pathway and procedures clear to parents/guardian	A B_	_CD _CD _CD
DC: W.	XIII. DISCHARGE PLANNING: Estimated date of follow up with resu Observe for recurrence of Major and Criteria and follow-up immediately Discharged from OPD, terminate path and refer to General Pediatrician	Minor A B;	_ C D _ C D
ACTIVATED BY:	ACKNOWLEDGED BY:		
ATTENDING PHYSICIAN/FELLOW-ON- DUTY Signature over Printed Name Date/Time	Signature over Printed Name	Signature over	HARGE (PM SHIFT) Printed Name